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CHAPTER I 
INTRODUCTION 
 Complex signaling pathways regulate the cellular processes that are 
required for proper development and function of life.  Transcription factors are 
vital to the expression of genes at specific time points within biological processes 
and are required for regulation of differentiation, morphogenesis, homeostasis, 
and further response to the environment.  In this chapter, the p53 family of 
transcription factors will be introduced with a particular focus on p73, and the 
process of multiciliated cell (MCC) development will be further discussed.  This 
dissertation focuses primarily on the discovery that p73 is necessary for the 
development of MCCs in mice, with an emphasis on the trachea and bronchiole 
epithelium.  This work identifies p73 as a regulator of MCC development, which 
may have implications for many pulmonary diseases and cancers that have not 
previously been linked to the activity of this transcription factor1. 
Discovery of the p53 Family 
p53 
  p53 was initially discovered as a protein in complex with the large T 
antigen in SV40-transformed cells2,3 and expressed in tumors4.  The tumor 
suppressive roles of p53 were demonstrated when inactivating mutations in p53 
were found in more than 50% of human tumors5,6 and germline mutations of p53 
were identified as being causative of Li-Fraumeni syndrome.  These findings 
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were strengthened when p53 was ablated in murine models, which developed 
normally but exhibited increased mortality due to spontaneous tumor formation7.   
 The tumor suppressive role of p53 is due to its ability to transcriptionally 
activate many genes involved in tumor suppression including Cdkn1a8 and 
Puma9 and many other genes that directly regulate the cell cycle, DNA damage 
repair, as well as apoptosis10-13.  These protective roles of p53 have lead many to 
commonly refer to the functional role of p53 as the “guardian of the genome”14. 
p73 
 A p53 homologous protein, p73, was discovered in 199715 and due to its 
high level of sequence identity with p53 it was initially thought to be redundant to 
p53 and primarily function as a tumor suppressor.  The generation of p73-
deficient mice discovered phenotypes that were unique from p53, including 
pheromonal, inflammatory, growth, and neurological defects16.  Further discovery 
and targeted ablation of multiple isoforms of p73 suggested that it can act as a 
p53 like tumor suppressor in certain biological contexts, but is much more 
complexly regulated17.  All of which will be further discussed below. 
p63 
 After the discovery of p73, through sequencing technologies the presence 
of a third p53-related protein was discovered18-20, and in 1998 p63 was 
discovered and functionally described21.  Its similarity to p53 suggested that p63 
may also be redundant to p53; however, the generation of the p63 deficient 
mouse revealed a unique biological role from the other two known family 
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members.  The ablation of p63 in mice leads to perinatal mortality due to severe 
developmental defects including a lack of stratified epithelia, absence of limbs, as 
well as craniofacial defects22.  The mice also lacked all glandular epithelial 
tissues including mammary, lachrymal, salivary, prostate, and bladder 
tissues22,23.  This initial discovery of p63 as a master regulator of epithelial 
development led many subsequent studies of its biological role in development. 
Similarity of p53 Family: Structure and Function 
The p53 family of transcription factors all descended from a single 
ancestral gene and to share a common domain structure and have a high degree 
of sequence identity24.  p53, p63 and p73 all share conserved domains including 
(N)-terminal transactivation (TA), DNA binding (DBD) and oligomerization 
domains25,26.  When comparing the whole amino acid sequence of the p53 family, 
p53 and p73 share 30% sequence identity, p63 shares 25% sequence identity 
with p53, and p73 shares 52% sequence identity with p63.  The identical amino 
acids are concentrated in functional domains of the p53 family for example, 60% 
of the amino acids are identical between the p53 family of proteins in the DBD  
with 100% conservation of the essential residues that contact DNA for all three 
family members27,28.  The most significant homology within the family is in the 
DBD of p73 and p63, with 87% amino acid identity (Figure 1A)29.  The shared 
DBD identity between the three proteins results in them all binding to the 
canonical p53 consensus response element made up of two half sites 
(RRRCWWGYYY - R=purine, C=cytosine, W=adenine or thymidine, G=guanine,  
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Figure 1. p53 Family Sequence Identity and Complex Splicing.  (A) Representation of 
the p53 family members with the known domains shaded in blue [Transactivating (TA)], 
purple [DNA binding domain (DBD)], green [Oligimerization domain (OD)], and gray [sterile 
alpha motif (SAM)].  Percentages between the known domains represent the sequence 
identity that is shared between each of the family members domains. (B) Cartoon 
representation of the 14 exon structure of the p73 gene.  Splicing is annotated utilizing 
lines with product of that splicing labeled.  The known domains of p73 are shaded in to 
annotate on which exon those domains are found.  Dashed line boxes indicate knockout 
mice that were utilized to study the biological function of the p73 gene.    
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and Y=pyrimidine) separated by a spacer of up to thirteen base pairs30-35.  
p6336,37 and p7335,37,38 are capable of binding to slightly different response 
elements, conferring responsiveness to independently regulated genes as well.  
The earliest p53 ancestor gene that has been identified to date exists in 
choanoflagellates, which are the closest extant relative of metazoans39.  These 
unicellular protists contain two distinct ancestor genes, one is more p53-like and 
the other is more p63/p73- like.  To date no p53 family member has been 
identified within fungi except for the Opisthokonts40.  p53-like genes exist in a 
broad number of taxa including sea squirts41, cnidarians42,43, and platyhelminthes 
extending throughout vertebrates.  The primitive metazoan sea anemone 
contains a p63/p73 hybrid called nvp63 that responds to UV light by inducing a 
DNA damage response resulting in apoptosis within the gametes43.  The p53 
response to DNA damage in the germline of this primitive organism is functionally 
similar to what is observed in many other organisms including Drosophila44,45 and 
mice46.  
Further biological complexity is conferred through the expression of 
alternate splicing and promoter use within the genes that code the p53 family. 
There are nine known isoforms of p53, six of p63, and 35 of p73 that arise from 
complex promoter usage and alternative splicing47,48.   p63 and p73 genes can 
be transcribed from different promoters and alternatively spliced to yield multiple 
protein products21,49.  p63 and p73 each have two upstream promoters (P1 and 
P2).  Isoforms transcribed from P1 contain the transactivation (TA) domain 
	 6	
(TAp63 and TAp73), and isoforms transcribed from P2 lack the TA domain 
(ΔNp63 and ΔNp73)15,21.   The N-terminus of TAp73 and TAp63 contains a single 
activation domain that is approximately 25% homologous with the first activation 
domain of p5350.  ∆Np73 contains 13 unique residues, which generate a much 
weaker activation domain allowing for abated transcriptional activation at target 
genes38.  Both ∆Np6351,52 and ∆Np7338 have been shown to directly activate 
target genes as well albeit at a significantly reduced rate from their TA containing 
counterparts TAp63 and TAp73 respectively.   Predominately the prescribed 
function of ∆N isoforms of p63 and p73 is attributed to be dominant-negative 
effectors of transcriptional activity of the p53 family of transcription factors38,50.  
p73/p63 Co-Association and Co-Regulation 
There are functional and physical interactions amongst the three family 
members, and co-regulation of many of the same target genes.  Three potential 
mechanisms for physical and functional interactions exist depending on cell 
context and relative levels of expression of the various isoforms. First, the 
regulation of transcription occurs through cooperation and competition at 
conserved p53/p63/p73 binding sites of shared target genes53-56.  Second, direct 
physical interaction of the p63 and p73 isoforms occurs23,57,58, because cells that 
co-express both p63 and p73  they associate59-61.  Third, mutant p53 protein that 
has lost tumor suppressive activity, which is expressed in numerous tumors, is 
capable of binding and inactivating p73 by either sequestering from the nucleus 
or inhibiting DNA binding62,63-72.  
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Shared consensus binding-sites between p53 family members indicate 
that they compete for binding at shared genomic binding sites when they are co-
expressed.  It is likely that this competition of binding is only exacerbated through 
protein-protein interactions that may be unique among family members.  All of the 
p53 family binds to DNA as tetramers in which the members interact through 
dimerization of dimers mediated by the oligomerization domain28,50,73. p73 and 
p63 are capable of regulating the function of each other73, and through this 
interaction in which ∆N isoforms bind with transcriptionally active TA isoforms 
and exhibit titration of their transactivation capabilities.  Also of interest, there is a 
p53 response element upstream of the ∆N isoforms of p73 and p63 promoters 
and p53 and TAp73 regulate their expression providing a negative feedback 
loop74-77.  In several cell types ∆Np63 isoforms are the predominate isoforms 
expressed16,78 it has been shown that in these systems the ratio of expression of 
∆N to TA regulates downstream transcriptional activity21. 
Complex Splicing of the p73 Gene Confers Complex Function 
The differential splicing of the C-terminus of p73 results in several 
isoforms that have different transcriptional activity79.  p73 is expressed highly as 
the TAp73α transcript in a majority of adult mouse tissues80.  For example, p73 
isoforms α and β are instrumental in normal myeloid differentiation, and γ,δ,ε, 
and θ have been linked to leukemic blasts81,82. The isoforms TAp73γ and 
TAp73δ are involved in terminal differentiation of human skin keratinocytes83.  
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However in some tissues, such as the lung, RNA and protein of all isoforms can 
be detected upon treatment with DNA damaging agents80.  
The differential function of p73 isoforms can be partially attributed to the 
alternate splicing of the C-terminal domains of p73.   One domain in particular the 
sterile alpha motif (SAM), is not conserved in all isoforms of p73 and p63 due to 
C-terminal splicing differences6.  This domain is conserved in many other 
transcription factors as far back as yeast and mediates protein-protein 
interactions.  It was coined as sterile, because of its presence in four proteins 
required for yeast sexual differentiation, and alpha because of secondary 
structure predictions of α-helices84.  Mutations in the p63 SAM domain are 
causative for AEC syndrome a developmental disease that causes ectodermal 
dysplasia and facial clefting85, while the p73 SAM domain binds to anionic and 
zwitterionic lipids86.  The SAM also acts in an inhibitory manner toward the 
transactivation domain of both p63 and p73 by possibly inhibiting the association 
of co-activators of transcription and the activation domains within the N-
terminus27.   Functionally, TAp73β is the most transcriptionally active isoform of 
p73 and it lacks the core of the SAM domain87,88.  
The C-terminal portion of p73 is not the only area in which p73 is spliced 
differentially to generate multiple isoforms.  Complexity also is conferred through 
alternative splicing within the N-terminus generating ∆ex2p73 and ∆ex2/3p73 in 
which exon 2 or exons 2 and 3 are alternatively spliced from the full length p73 
henceforth collectively called ∆TAp73 (Figure 1B)89,90.  These isoforms lack all or 
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the majority of the transactivation domain and they differ from ∆Np73 in that their 
transcription is driven from P1 promoter upstream of exon 1.  The study of these 
isoforms has been predominately limited to their role in tumorigenesis and has 
been shown to be biologically similar to ∆Np73 and to be preferentially expressed 
in tumors89-93.  Much like ∆Np73, the ∆TAp73 isoforms retain their DNA-binding 
and tetramerization abilities and act as dominant-negative inhibitors of the rest of 
the p53 family75,93-95.  ∆TAp73 isoforms are biologically relevant oncogenes in 
many culture systems75,93-95.  ∆TAp73 overexpression in NIH3T3 cells drives 
malignant transformation to produce tumors in nude mice93 as well as interferes 
with the Rb tumor suppressor pathway96. The ∆TAp73 isoforms are upregulated 
in many cancer types and further correlates with poor survival 90,97,98.  As high 
throughput deep sequencing of human samples becomes more readily available 
it will be of great interest to determine the expression of N-terminal and C-
terminal isoforms to determine their role in normal tissues and disease states. 
p73 Function Determined by Knockout Murine Models 
 There have been multiple murine p73 genetic models developed that 
target multiple domains within p7316,99-105.  These engineered models are 
annotated in Figure 1B (dashed boxes).  The global ablation of p73 by targeting 
exons within the DBD16, which resulted in hippocampal dysgenesis, 
hydrocephalus, sterility, chronic infections and inflammation of the lung and 
sinus, abnormalities in the pheromone sensing pathways, runting, as well as 
increased rates of postnatal death16.   
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After the generation of this model, subsequent studies were focused on 
the neurological defects observed in p73-deficient animals.  In p73 null mice the 
brain lacked expression of Reelin leading to the hippocampal dysgenesis 
observed16.  The expression of ∆Np73 in murine brain provides an anti-apoptotic 
pro-survival signal that leads to the maintenance of the neural stem progenitor 
cells102,106.  More recently, p73 activity has been implicated in the development 
and maintenance of ependymal cells107,108.  It was observed that the ependymal 
cells in p73-deficient animals were increasingly apoptotic and exhibited 
dysfunctional cilia architecture107.  A second study did not observe apoptosis 
within the ependymal cells of p73-null animals, but noted a denuding of 
ependymal cells due to lack of differentiation from radial glia cells into ependymal 
cells causing the loss of the motile cilia in the process resulting in hydrocephalus 
and hippocampal dysgenesis108.  
The use of global pan-isoform targeting murine models failed to parse the 
individual functions of the multiple p73 isoforms, which confounded the complex 
biology of this transcription factor.  For example, two murine models that ablate 
∆Np73 expression as well as TAp73 expression independently17,99 revealed a 
role of p73 in neurodegeneration, but those mice did not exhibit the sterility 
phenotypes observed in the p73-/-.  ∆Np73 knockouts also exhibited increased 
levels of apoptosis and expression of p53 family target genes confirming the anti-
apoptotic function of p73 in vivo. Injection of E1A and Ras transformed ∆Np73-
deficient MEFs into athymic nude mice resulted in smaller, slower growing 
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tumors when compared to those transformed from wild-type animals suggesting 
that ∆Np73 expression is important for transformed cells to initiate tumors99. 
Isoform specific deletion of TAp73  in mice caused infertility, hippocampal 
dysgenesis, expedited aging, genomic instability, and increased frequency of 
carcinogen-induced tumors17. The oocytes of TAp73-/- mice exhibited spindle 
abnormalities leading to genomic instability within the female mouse follicle 
development17.  TAp73-/- male mice also exhibit severely impaired 
spermatogenesis resulting in increased DNA damage and apoptosis of 
spermatogonia101 leading to a nearly empty seminiferous tubule103.  TAp73 also 
regulates the adhesion and migration factors that uphold the germ-sertoli 
connection that is required for proper spermatogenesis103.  Other studies 
indicated that the transactivation activity of TAp73 at target genes required for 
mitochondrial function, such as Cox4i1, was required for processing reactive 
oxygen species.  The knockout mice revealed increases in senescence and 
oxidative damage from reactive oxygen species leading to premature aging100.   
Like the ∆Np73-null mice, the TAp73 ablated mice exhibit hippocampal 
dysgenesis and hydrocephalus indicating that all isoforms of p73 are necessary 
for proper neural development17.  The peripheral nervous system of the TAp73 
mice is also affected due to the absence of p73 transactivation of the p75 
neurotrophin receptor, which resulted in a loss of sensory but not motor 
neurons105.  These isoform knockouts indicate that the p73 isoforms, studied to 
date, exhibit independent and co-dependent roles within development.  Further 
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studies of c-terminal variants will further enable greater understanding of 
biological roles of all of the other isoforms commonly expressed. 
The Role of p73 and p63 in Tumors 
Unlike p53, p63 and p73 are rarely mutated during tumorigenesis6,109-111.  
Although p63 and p73 can activate apoptosis in vitro21,53,112-114, it is clear that 
they are not classic Knudson-like tumor suppressors.  The human p63 gene 
maps to 3q27-28, a region frequently amplified in squamous cell carcinomas115-
117, with overexpression also reported independently of gene amplification118. 
ΔNp63α is overexpressed in ~80% of head and neck squamous cell carcinoma 
(HNSCC) and in other epithelial cancers including lung23,58,117,119-122. p63 is 
amplified in 88% of squamous carcinomas, 42% of large cell carcinomas, and 
11% of adenocarcinomas of the lung110.  ∆Np63a was the predominant isoform 
expressed at the protein level within these tumors110, which suggests that p63 
genomic amplification has an early role in lung tumorigenesis110.   Although 
reported levels of p63 expression in breast carcinomas have varied123-128, 
elevated p63 levels have been noted in a subset classified by a ‘basal’ 
phenotype129.  
For select tumor types, overexpression of ΔNp63α has been associated 
with favorable outcome117,130, and for others, loss is associated with invasion, 
metastasis and poor outcome90,122,131,132.  One hypothesis to reconcile these 
findings is that in early tumorigenesis, ΔNp63α contributes to maintaining a self-
renewing epithelial state and allowing growth in a local tumor-host environment; 
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however, as cells accumulate additional genetic events, loss of p63 facilitates an 
epithelial to mesenchymal transition enabling migration 130.  
p73 is overexpressed, rather than mutated or deleted, in a large number of 
tumor types6.  ΔNp73 or ΔNp63 overexpression or loss of TAp73 may be 
required to inactivate presumptive tumor-suppressive properties of 
TAp7323,58,91,133-136.  In head and neck squamous cell carcinoma (HNSCC) and 
’basal-like’ breast cancer cell lines, ∆Np63:TAp73 complexes suppress p73-
dependent apoptosis through direct protein interaction and competition for 
binding at key target genes.  The latter is supported by in vivo evidence in these 
tumor types23,58,136.  The ability of either ∆Np63 or ∆Np73 to inhibit TAp73 may 
obviate the need for mutation of p73 during tumorigenesis.  There is evidence 
that p73 is important in the pathogenesis of lung cancer137-139.  Loss of 
heterozygosity (LOH) at the p73 locus is reported in 62% of squamous cell 
carcinomas found in the lung140, and the p73 G4C14-to-A4T14 polymorphism is 
associated with increased risk of lung cancer141 (discussed in detail in the 
following section).  
p73 in Lung Cancer 
Thirty percent of TAp73+/- mice and 73% of TAp73-/- mice developed 
malignancies with lung adenocarcinoma being the most frequently observed 
cancer representing 44% of all tumors observed in TAp73-/- mice17.  The lung 
adenocarcinomas observed in knockout mouse models as the primary tumor 
produced in a p73 ablated state led many to research the role of p73 in lung 
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tumorigenesis.  Unlike its family member p53, the coding sequence of p73 is 
rarely mutated even within lung tumors6. 
Expression of p73 Within Lung Cancers 
 In initial studies after the discovery of p73, most looked at pan p73 
expression, with no knowledge of splicing variants, across cancers.  In one such 
study, 87% of patients’ p73 is overexpressed while only 5% of patients have 
reduced expression of p73 as compared to normal controls142.  In later studies, 
∆Np73 was shown to be significantly overexpressed in higher staged lung tumors 
from patients, and its expression indicated poorer prognosis and outcome in 
patients with high expression143, by an increase in the risk of death by a factor of 
3.38143,144.  Others noted in non-small cell lung cancer (NSCLC) that the mRNAs 
for ∆ex2p73 and ∆ex2/3p73 were higher expressed while other isoforms were 
down modulated145.  Interestingly in many of the studies of p73 expression in 
NSCLC localization of TAp73 appears to shift from the nucleus to the 
cytoplasm143-146.   
Further investigation of the p53 family indicated that ∆Np63 is highly 
overexpressed, while TAp63 is expressed at lower levels in squamous cell 
carcinoma (SCC) while overexpression in adenocarcinoma is not observed144,145.  
A study investigating the role of alterations within ARF, p53 and p73 in NSCLC 
noted LOH of p73 in cases where either and/or p53 were abnormal147.   
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Promoter Methylation Shift  
 There are two CpG islands localized at the P1 and P2 promoters.  The 
larger of the two is found at the P1 promoter and was hypermethylated in 
hematopoetic cancers but rarely within other tumors148-153.  The smaller CpG 
island correlating with P2 is almost always fully methylated under normal 
conditions within tissues151,152.  In a few studies of NSCLC both TAp73 and 
∆Np73 were observed to be overexpressed in a majority of cases146,154-156.  P1 
promoter was very rarely hypermethylated at 6.8%155 but generally observed to 
be unmethylated.  These studies showed that the P2 promoter was 
hypomethylated within the tumors but hypermethylated in the normal tissues 
used as controls146,155.  P2 hypomethylation was observed to be most frequent in 
SCC155, indicating that unrestrained expression of ∆Np73 may shift the balance 
from the transcriptionally active TAp73 isoforms that suppresses tumorigenesis. 
G4C14-to-A4T14 Polymorphism and Lung Cancer 
 A G4C14-to-A4T14 dinucleotide polymorphisms is present in  
neuroblastoma, and it forms a stem loop structure that affects the expression of 
TAp7315.  This polymorphism is observed three base pairs from the splice site for 
exon one and exon two of TAp73.  It is also twenty base pairs from the initial 
methionine of TAp73.  Many publications indicate that this polymorphism occurs 
in approximately 20% of lung cancer patients141,157-160.    Two studies indicated 
that G4C14-to-A4T14 increased the risk of tumors in a dose dependent manner 
depending on the allelic frequency of the polymorphism141,157.  However, the 
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polymorphism was protective against the development of lung tumors161.  All of 
these were combined as individual case controlled experiments into one large 
cohort, and it was observed that the polymorphism was not associated with the 
development of lung cancer in the Asian populations as initially described. 
However, the polymorphism was correlated with cancer risk in the studies that 
pooled the data from Caucasian populations with lung cancer162.  
The G4C14-to-A4T14 polymorphism appears to correlate with lung 
tumorigenesis within some races or sampling sets published, but it does not 
confer risk across all populations and is likely linked to other factors of 
tumorigenesis.  A study of Korean lung cancer patients observed a correlation of 
p73 polymorphisms and lung cancer risk, which was observed to be significantly 
higher in the patients that also exhibited the MDM2 309T-309G polymorphism163. 
A more recent study, p73 G4C14-to-A4T14 and MDM2 309T-309G conferred 
decreased survival of patients with NSCLC when measured in combination with 
p53 R72P164.  More studies of the correlation of this p73 polymorphism in 
reference to other mutations or polymorphisms in the p53 signaling network are 
needed to better understand the conflicting results observed across the published 
literature in reference to the G4C14-to-A4T14 polymorphism. 
Pulmonary Development 
 The pulmonary system is a complex arrangement of branches stemming 
from the tracheal tube leading to alveolar structures where the capillaries are 
closely proximal to the epithelium to allow for the exchange of oxygen and carbon 
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dioxide required for life.  Each minute the human lungs bidirectionally process 
approximately six liters of air165 over approximately 70 m2  of surface area166.  
The air that is processed in the lungs carries with it many contaminants and 
pollutants that must be processed and controlled to protect the underlying cells.  
The lungs have developed methods for transport of those toxins, how much 
space they cover, air exchange, how much mucous is moved out daily. 
Initiation of Lung Development 
  Early growth of the lung has been organized into five periods of 
development that occur during precise times in mouse/human: Embryonic (M: 
E9-11.5 / H: 3-7 wk gestation), Pseudoglandular (M: E11.5-16.5 / H: 5-17 wk 
gestation), Canalicular (M: 16.5-17.5 / H: 16-26 wk gestation), Saccular (M: 
E17.5-PN5  / H: 24-38 wk gestation), and Alveolar (murine PN5-28 / H: 38 wk 
gestation to maturity) (Figure 2).   Initiation of lung buds occur in the embryonic 
period of development when cells marked with the expression of TTF1 and 
Foxa2 transcription factors167-169 proliferate and differentiate from the primitive 
oesopagus170,171.  In order for proper branching of the lung, cells must migrate 
from the foregut endoderm-derived epithelium into the splanchnic mesoderm 
forming the respiratory bronchioles and alveolar spaces integrating 
vascularization and surfaces for air exchange170.   
The respiratory branching tree continues into the pseudoglandular stage of 
development, during which the bronchiole branches are lined with 
undifferentiated epithelial cells172.  During this phase of development 
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E12-E15
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Figure 2.  Stages of Pulmonary Development.  Overlapping stages of lung maturation 
take place through a series of branching  and developmental changes.  The top labels 
annotate the gestation time at which the lung develops within both mouse and human.  
Cartoon depictions of the stages of development are shown below.  The epithelial cell types 
observed throughout the murine epithelium are shown at the bottom corresponding to the 
time at which they can first be observed to develop in the lungs. 
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 vasculogenesis and angiogenesis establish pulmonary veins and lymphatic173  
smooth muscles cells differentiate along the bronchial tubes174,  and cartilage 
develops along the trachea and bronchi175 establishing the structure on which the 
various pulmonary epithelial cells can differentiate late in the pseudoglandular 
stage and through the canalicular stage.  In rodents, lungs continue to grow 
throughout the life of the animal keeping pace with the size of the body, but that 
pace of growth slows with age176.  The consensus for the epithelial cell turnover 
in adult mice is greater than 100 days177,178 with multiciliated cell turnover rate is 
much slower with a significant number of cells still present at 18 months of 
age179.  Thus the pulmonary epithelial cells that develop prior to birth are present 
when the animals reach maturity, and some are still present at the animal’s 
death.  
Pulmonary Epithelial Cell Milieu 
 Before the end of the pseudoglandular to canalicular stage transition of 
development the cells lining the trachea and bronchioles remain undifferentiated, 
but in later development these cells must differentiate into several cell types 
including; neuroendocrine, brush, multiciliated, club, basal, and goblet/mucin 
cells (Figure 2).  It is the balance of these epithelial cells, described in more detail 
to follow, that permit proper breathing and pulmonary health. 
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Neuroendocrine Cells 
Neuroendocrine cells first appear in proximal conducing airways during the 
end of the Pseudoglandular stage of development (Figure 2) then later at the 
sites of airway branches and distal airways, creating a proximal to distal wave of 
development in developing pulmonary epithelium180-183.  Precursor 
neuroendocrine cells become innervated by ganglion cells and can then 
proliferate to become neuroepithelial bodies181, which regulate the further 
proliferation and development of adjacent epithelial cells180,184-186.  The 
neuroepithelial bodies also act as focal sites for secretory cell 
differentiation180,184-186.   
Neuroendocrine cells are sensors of damage in the lung, and their 
frequency increases in conditions of prolonged hypoxia187 and in many lung injury 
models188.  For example they act as the primary O2 sensing chemoreceptors 
within the lung189.  These cells express both neural and endocrine phenotypes189.  
They secrete dopamine, serotonin, gastrin-releasing peptide and somastostatin 
189-191.  These factors assist in the transition of the lungs to postnatal life by 
regulating the ion and fluid transport; for example, dopamine is highly expressed 
at birth and assists in increasing Na+ channel and Na+/K+ ATPase activity192,193 
and serotonin a similar function194.  In the pulmonary system, neuroendocrine 
cells are early-differentiated cells that lay the signaling groundwork for the further 
development of the epithelial cells to follow and regulate the transition from in 
utero to postnatal life182,183,190,195. 
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Brush Cells 
 There is a highly viscous mucous layer of protection within the airways 
and under that layer there is a lower viscous layer of liquid lining the airway 
surface that is made up of antimicrobial substances, amino acids, and 
lipids196,197.  The balance of these layers must be maintained for healthy 
respiration.  The brush cells provide a chemosensory role for the pulmonary 
epithelium to maintain the correct protective balances of cells and secreted 
factors within the airways.   
 The first description of a brush cell in rat trachea was identified as an 
isolated cell with the presence of a “brush” of microvilli with long rootlets that can 
reach as far as the pairnuclar region198.  These cells make up approximately 0.5 
percent of all epithelial cells within the murine tracheal epithelium199-202.  They 
were later identified in human00 lungs203 and digestive tract204,205 and are 
concentrated in the gallbladder204-206.  Several bitter taste-related molecules link 
the brush cell to the taste bud and indicates it may be operating in a 
chemosensory role207.  For many years brush cells were identified in the airway 
epithelium by ultrastructural imaging to observe the tuft of microvilli and rootlets 
and now can be immunostained with villin and fimbrin208.  
Brush cells in the trachea are directly contacted by nerve fibers205 that 
stem from the sensory vagal ganglia201,209.  Brush cells detect bitter-tasting 
molecules released by bacteria in the nose209 and trachea210 and likely other 
signals of change within the pulmonary epithelium.  Brush cells respond to stimuli 
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by coordinated release of local responses for the surrounding tissue but also 
through activation of the connected sensory nerve fibers initiating avoidance as 
well as defense211,212.  In the trachea and lungs this generally results in a cough 
reflex or decreases in the frequency of breathing as well as altered cellular 
secretions201,213,214  
Multiciliated Cells 
Airway MCCs are terminally differentiated cells that are not capable of 
self-renewal180 and are first observed at the end of the pseudoglandular stage of 
pulmonary development (Figure 2)165.   In a tissue-specific manner, epithelial 
cells generate 200-300 individual cilia (multicilia) to aid in motility or movement of 
fluids in those tissues215.  Maturation of a ciliated cell only is considered 
completed when the ciliated border of the cell is full of the proper number of 
motile cilia and the actions of the organelles is fully coordinated180.  Motile cilia 
are generally comprised of 9 microtubule doublets surrounding a central pair of 
microtubules (9+2).     Motility in cilia is derived from the coordinated activation 
and inactivation of dynein proteins that line the inner and outer dynein arms along 
the entire axoneme216,217.  The motility of these cilia is required for mucocilliary 
clearance in the respiratory tissues218,219 and also for ependymal flow within the 
brain220. Comparisons have been made between respiratory MCCs and those of 
the sinus, oviducts, epididymis, and ependymal compartment.  The ependymal 
cilia beat approximately twice as frequently as the cilia found in the respiratory 
system and are significantly longer at 8 µm as compared to 5 µm in the airway221.  
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There are also far fewer cilia per cell in the ependymus with an average of 16 
cilia per cell222.  
Within the pulmonary system of healthy humans the coordinated beating 
of cilia propel mucus 4 to 20 mm/min223.  The cilia only touch the mucous layer 
on the forward stroke and pass underneath it on the backward stroke224,225 to 
propel it through the vocal cords and pharynx223.  Healthy cilia are a requirement 
for proper pulmonary function, and the complex process of multiciliary biogenesis 
and homeostasis is described in more detail in further sections. 
Club Cells 
Club cells are non-mucous, non-serous cuboidal secretory cells226-228 that 
are club shaped with a luminal surface that extends above the surrounding 
epithelial cells.  Their differentiation initiates at the beginning of the canalicular 
stage of pulmonary development (Figure 2)165.  They were initially identified due 
to the granules that contain surfactants that were observed to be secreted from 
these cells229-231.  Club cells also produce P450 enzymes that are required for the 
metabolism of inhaled pollutants232,233.  The balance of club/ciliated cells is of 
extreme importance within the pulmonary epithelium, because together they 
regulate the balance of mucosecretory ciliary clearance of the lung.  Within the 
tracheal epithelium, the balance is shifted to require more frequent ciliated cells 
and a few club cells, while the bronchiole epithelium contains an abundance of 
club cells in comparison to ciliated cells234-236.  It has been previously reported 
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that the Notch pathway is a necessary factor in the development of the club cells 
by regulation of the club/ciliated cell fate decision237-240.  
 Club cells retain stem like capabilities throughout the life of an organism.  
After administration of external damaging agents                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
club cells were capable of generating basal cells, albeit at very low efficiency241.  
They were previously shown to be capable of self-renewal and differentiation into 
MCCs242-244.  Other studies in the prostate245 and other organ systems show that 
daughters of stem cells can revert to regain stem characteristics after injury246.  
Lineage tracing experiments indicated that the pulmonary epithelial cells that 
result from de-differentiated club cells are replaced over time by basal cell 
proliferation, and thus, club cells do not de-differentiate into functional long term 
stem cells of the lung241.   
Basal Cells 
 Thirty percent of the pseudostratified epithelium of the murine trachea is 
made up of basal cells234,235 that express p63235, cytokeratin 5 (Krt5)247, and 
cytokeratin 14 (Krt14)234,248,249.  Basal cells in the uppermost tracheal epithelium 
form a monolayer but are distributed in clusters in the more distal trachea and 
upper bronchioles of mice249, and can be observed just before birth at the 
termination of the saccular development stage (Figure 2)165.  The differentiation 
of basal cells that takes place late in utero and completes postnatally is 
dependent upon the expression of p63250.  It is hypothesized that there are 
multiple basal cell types within the pulmonary epithelium that exhibit varying stem 
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cell capacity for re-population of epithelial cell types171,235,236,251.  Most basal cells 
express Krt5 and only a smaller subset express Krt14 until the epithelium 
undergoes toxic damage (e.g. naphthalene injury), upon which Krt14 cells greatly 
expand and recapitulate the many epithelial cells234,248. 
 Through lineage tracing experiments, basal cells proliferate into daughter 
basal cells as well as differentiate into ciliated and club cells234,235,248. Tracheal 
epithelial cells can be individually sorted and in clonal tracheosphere experiments 
determined that p63+/Ngfr+/Krt5+ cells were the cells that self-renewed and 
repopulated epithelial cell types235,251. 
In unchallenged lungs, we hypothesize that it is the balance of p63 
isoforms that allow a subset of cells to maintain proliferative potential while 
maturing into stratified epithelium. At E15.5 stem cells of the esophagus and 
trachea express p63 and within the tracheal epithelium those cells first 
differentiate into MCCs and later into the p63 expressing Basal cells250.   Unlike 
the skin where p63 loss leads to loss of the epithelium, ablation of p63 in mice 
did not result in absence of the tracheal and esophageal epithelium but results in 
hyperciliation of the trachea and bronchioles of developing embryonic animals250.  
In human bronchiole epithelial cells (VA10 cell line) that can differentiate into a 
stratified pulmonary epithelium in culture252 ∆Np63 expression mimics what is 
observed in murine knockout models253. 
p63 has been shown to provide the molecular switch that initiates and 
regulates epithelial stratification in the tissues where it is expressed254.  Ectopic 
	 26	
expression of TAp63 in alveolar cells led to the expression of Krt5 and Krt14 and 
further stratification of alveolar cells254.  Also, when airways are damaged due to 
infection a wide-ranging regeneration must take place to repopulate both the 
alveolar spaces as well as the epithelial cells.  Club cells act as progenitors in the 
repair process of bronchiole epithelium241; however, after damage by H1N1 
infection or bleomycin treatment, p63-positive cells proliferate and migrate255 to 
areas of damage and begin the process of reconstruction of the both the alveolar 
cell types255,256.  Further ablation of these p63-positive cells inhibits the lung 
repair and leads to pre-fibrotic lesions and reduced oxygen exchange257. 
Goblet/Mucin Cells 
   The lung is coated with a bilayer of differentially viscous liquids that 
provides protection from external toxin damage to the underlying epithelial cells.  
The upper mucus layer comes in contact with inhaled air while there is a sterile 
periciliary layer that contacts the underlying epithelial cells258,259.    The topmost 
of the highly viscous mucus contains large heavily glycosylated proteins also 
known as mucins, for which there have been over 20 mucin genes identified to 
date260. The most abundantly expressed mucin genes in the goblet cells are 
MUC5AC and MUC5B223,258,260,261.  The function of the mucus layer in the lungs 
is to trap inhaled particles and other toxins including bacteria and viruses262-264.  
In humans the mucins are secreted by the submucosal gland and goblet cells of 
the respiratory epithelium; however this layer is generated in mice solely from the 
mucous cells also known as goblet cells that are stimulated by inflammatory 
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responses predominately after birth (Figure 2)264.   During normal physiological 
states murine lungs are nearly devoid of goblet cells; however, in human lungs 
there are goblet cells present without damaging events258.  Goblet cells can arise 
from both the differentiation of basal cells235,265-267, as well as from the club cells 
in response to damaging allergens, inflammation or other toxins259,265. 
 The differentiation of Goblet cells must be tightly regulated for proper 
function of the pulmonary epithelium and air exchange.  If goblet cells produce 
excessive mucins it can change the viscosity of the mucus throughout the 
pulmonary system and not allow for proper mucociliary clearance, which leads to 
many diseases258-260,268.  The Notch pathway has been determined to be active in 
the proliferation of the goblet cells, through its activation in the basal cells267 or in 
the differentiated club cells of the pulmonary epithelium237.  Loss of Notch lead to 
loss of the club and goblet cells with increases in the frequency of ciliated 
cells238,240.  On the other hand, FoxA2 inhibits the differentiation of goblet cells in 
the airways.  The expression of Foxa2 is inhibitory of the goblet cell gene 
expression269.  Foxa3 and Spdef regulate each other as well as promote the 
expression of genes observed within goblet cells270,271. 
Ciliary Development Within Multiciliated Cells 
Discovery and Description of Cilia  
 Cilia were first observed by Antonie van Leeuwenhoek in 1676, making 
them the first organelle to be discovered272,273.  Cilia are membrane bound 
microtubule cores that extend from a basal body.  The innermost cytoskeletal 
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structure that makes up the cilia is referred to as the axoneme274.  The axoneme 
structure is made up of 9 radial doublets of microtubules that may or may not 
surround an inner/central pair of microtubules, 9+0 and 9+2 configurations 
respectively, depending upon the function of the cilia.   
Many cells within vertebrates generate a monocilium (primary cilia).  
Unlike the other cellular organelles, cilia are only generated after a cell has exited 
the cell cycle into a quiescent and/or differentiated state275.  The primary cilia 
arise from a single basal body, formed by 9 doublet microtubules (9+0) but lack a 
central pair of microtubules.  The basal body that this cilia is fixed to is the 
centriole that the cell used to split during mitosis.  During interphase the centriole 
attaches to the membrane and microtubule assembly takes place directly onto 
the centriole216,276.  These primary sensory cilia act as an antenna for receiving 
and sending both intracellular as well as extracellular signaling events277-280. 
Differentiation and development of multiciliated cells 
For MCC differentiation, cells will initially develop a primary cilia some 
days before developing the fully ciliated border281.  The development of cilia is a 
highly synchronized process that follows a consistent and tightly regulated 
process.  Cilia are generated beginning with cell cycle arrest followed by basal 
body amplification/duplication, which then dock to the apical cellular membrane 
and further develop motile cilia282.  Basal bodies in ciliated cells can arise directly 
from pre-existing centrioles as well as independently from centrioles within 
deuterosomes in close proximity to the centrioles that already exist281,282.  The 
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deuterosome acts as an organizational center for the basal bodies of ciliated 
cells281.  Basal bodies are generated in a highly organized and wave like manner, 
and the construction of cilia begins as soon as each wave of basal bodies are 
completed281.  The forming basal bodies associate with membrane vesicles that 
later fuse with the membrane, which establishes the cilia/membrane 
compartment.  At the base of the cilia, in many organisms and tissues, the basal 
body and plasma membrane forms a transition zone that includes a ciliary 
pocket, which is an invagination of the membrane and regulates the movement of 
factors between the cytoplasm of the cell and the cytoplasm within the cilia283. 
Microtubules are assembled exclusively at the distal end of the cilia284, and since 
proteins are synthesized in the cytoplasm the elongation of the cilia requires 
intraflagellar transport (IFT) through kinesin and dynein motor-based 
transport282,285. 
Cilia and Disease 
Patients with heart and abdominal viscera positioned in a mirror image to 
normal placement (also called situs inversus) also exhibited respiratory 
problems286.  This disease was initially called Kartagener’s Syndrome (KS) but 
was later grouped with other ciliated diseases into a larger grouping term of 
primary ciliary dyskinesia (PCD).  More recent data incorporated right left 
randomization and respiratory illnesses both due to loss of motile cilia.  A motile 
monocilia is observed at the node of developing mammals during embryogenesis 
that rotate in a clockwise direction creating a “nodal flow” of fluids287.  When the 
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nodal cilia are either immotile or absent the nodal flow is deregulated and this 
leads to randomization of situs288-290, as well as heart looping or randomized 
organ turning288,291. 
Some of the first patients that were diagnosed with a motile cilia disease 
were initially characterized in Denmark and Sweden, when the spermatozoa in 
sterile men were determined to be lacking the dynein arms within their individual 
flagella292,293.  The patients also exhibited chronic rhinitis, sinusitis, bronchitis, 
and otitis.  When both the tracheal294 and bronchiolar295 ciliated epithelium were 
investigated they also lacked dynein arms in these patients.  Patients exhibiting 
these symptoms began to be grouped under the broad PCD diagnosis.   
PCD is a heterogeneous diagnosis that is in reality a group of mostly 
autosomally recessive inherited genetic disorders that affects one in twenty 
thousand individuals at birth296.  In patients with PCD, the airway cilia can be 
immotile, dysmotile, or absent causing the symptoms above.  Many patients with 
PCD also exhibit asthma as well, and all of these respiratory characteristics 
combined can lead to the dilation of the bronchial airway, bronchiectasis, which is 
highly destructive to respiration286.  Male infertility is very common in PCD due to 
immotility of sperm297,298.  However, female sterility is infrequent in PCD.  It has 
been shown that female patient infertility can be due to dysfunction among the 
motile cilia lining the fallopian tubes and uterine lining298. 
Hydrocephalus is a condition characterized by accumulation of 
cerebrospinal fluid in the ventricles of the brain.  There are a few causes of this 
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condition including impaired cerebrospinal fluid flow, excess production, or lack of 
reabsorption299-301.  Hydrocephalus caused by impaired fluidic flow of 
cerebrospinal fluid has been linked to abnormal or dysfunctional cilia within the 
ependymal cells lining the cerebral aqueduct220,299,302 . 
Transcriptional Control of Ciliary Development 
Regulatory Factor X Transcription Factor Family 
 The regulatory factor X (Rfx) family of transcription factors regulates the 
expression of the components of the different types of cilia utilized in multiple 
tissue types303.  All members within this family contain a winged-helix DNA 
binding domain that binds either as monomers or dimers within the minor grove 
of DNA303 to X-box regions found in promoters of many genes.  There have been 
eight individual mammalian Rfx family members identified304-307 that are named 
Rfx1- Rfx8 respectively, and all of these eight are found within all vertebrates 
analyzed except within fishes where there are 9 Rfx factors308.   
 Rfx5, Rfx7, and Rfx9 regulate biological functions outside of ciliary 
biogenesis, while Rfx1-Rfx4, Rfx6, and Rfx8 are evolutionarily conserved in the 
process of ciliary biogenesis308.  Inactivation of any one of these factors results in 
mild defects of ciliogensis, indicating that there is functional redundancy and 
cooperatively among the different factors due to overlapping expression within 
MCCs309-311.  The Rfx gene family is capable of homo- and hetero-dimerization at 
DNA binding sites indicating coordinated and interdependent transactivation of 
target genes304,311,312.  Many of the genes regulated by the Rfx family encode 
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components of core ciliary biogenesis  processes including structural 
components of the basal body and axoneme as well as components of the 
intraflagellar transport machinery313-316, which leads to the specification of 
precursor cells into ciliated cell types313,315,316. 
Forkhead Box Gene Family, Foxj1, Role in Ciliogenesis 
 The Fox genes regulate transcription and were named after the Drosophila 
melanogaster gene fork head (fkh).  This gene, when mutated, resulted in 
involution of the drosophila head during embryogenesis resulting in a head spike 
in adult flies317.  Fox genes are present in saccharomyces cerevisiae (four genes) 
to humans (50 genes) and are subclassified into 19 subfamilies (e.g. Foxj1). The 
canonical forkhead domain directly binds to DNA is homologous between all 
species in which the Fox genes are expressed318.  The canonical forkhead 
domain, also referred to as a winged-helix structure, is made up of three β-
sheets, three α-helices and two ‘wing’ regions flanking the final β-sheets, and 
through structural studies binds to DNA as monomers, contacting DNA by the 
third α-helix and two wing structures319-323.  The wing structures of the fork head 
domain dictate specificity and affinity of the proteins for their respective target 
sequences323. 
 Several proteins from the subgroups of the Fox family contain two nuclear 
localization sequences (NLS)324-326.  Of the two NLS, the one in the C-terminal 
portion of the forkhead domain is more highly conserved 324.  Thus, it is 
hypothesized that it acts as a common nuclear transport signal that is shared for 
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all Fox family members.  Although the Forkhead domain is highly conserved 
between all members of the Fox family, the regions that flank this DBD contain 
poorly conserved highly specific effector domains that regulate the fox family 
functions.  For example, some forkhead factors can act in tandem with other 
families of proteins through direct binding domains including the SMAD3 effector 
of Tgf-β, STAT3, or HoxA5327,328.   
 A wide overview of Fox family member expression in human tissues 
indicates that the vast majority of the family proteins are expressed in a very 
selective/tissue-specific manner329.  A small portion of the family members are 
expressed nearly ubiquitously across all tissues330.  The tissue specific 
expression of the individual members of this family is thought to give rise to a 
wide array of activity within this family of genes.  One would hypothesize that the 
tissue specific expression of each of these proteins leads to a very diverse role of 
Fox family genes in development and homeostasis of the tissues in which they 
are expressed.   
FoxJ1 was first cloned from a rat lung cDNA library by PCR of the 
forkhead domain331.  In situ hybridization showed that the expression of FoxJ1 
was restricted to the mammalian tissues that require motile cilia204,331-333.  FoxJ1 
nuclear expression accumulated prior to ciliogenesis in the lung, trachea, 
oviducts, spermatids, and ependymal cells334-336.  FoxJ1-deficient animals 
exhibited a complete loss of axonemes and motile cilia of the airways, oviducts, 
ependymal cells and also exhibit left-right asymmetry defects337,338.  In the 
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deficient animals cells, the basal body docking to the cell membrane was 
impaired, but the amplification of basal bodies was not impaired337,339,340.  Thus, 
FoxJ1 stimulates the later stages of multiciliogenesis in addition to ciliary 
commitment341.  A transgenic mouse missexpressing Foxj1 off of the surfactant 
protein C promoter (commonly expressed in club and alveolar cells) triggered 
ectopic cilia formation in cells, which caused links between the alveoli that do not 
naturally produce cilia334,335. 
The role of Foxj1 in ciliary biogenesis is conserved across many species 
including xenopus and zebrafish342,343. Forkhead-like 13/hepatocyte nuclear 
factor 3 forkhead homolog 4 (Foxj1) is thought to be the oldest family member, 
and is found in the opisthokont, the last common ancestor of Fungi and 
Metazoans344.  Of note, p73 is also expressed in this evolutionary ancestor40. 
Mcidas and Myb 
Recently, multicilin [MCI (Xenopus) or Mcidas (mouse)] was identified;  it 
is a coiled-coil protein that is negatively regulated by Notch and highly expressed 
in developing epithelia where MCCs form345.  Inhibiting MCI specifically blocks 
MCC formation in Xenopus, whereas ectopic expression induces the 
differentiation of MCCs in ectopic locations.  Multicilin activates gene expression 
required for MCC formation, including FoxJ1, and genes mediating centriole 
assembly.  Although Mcidas has a coiled-coil domain and can activate 
transcription if tethered to the DNA through fusion with a DBD, it has not been 
shown to directly bind DNA345 and likely functions as a co-activator of 
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transcription.  It is thought to be necessary and sufficient to promote MCC 
differentiation in MTEC cultures345.  
   Myb is a transcription factor encoded by the myeloblastosis proto-
oncogene and is a member of the Myb family of TFs involved in cell cycle 
regulation and progenitor cell proliferation341.  Myb is expressed in post-mitotic 
epithelial cells of the mouse airways destined to become MCCs and is thought to 
promote centriole amplification and the later steps of the multiciliogenesis 
program346.  Conditional inactivation of Myb in the developing airway delays 
centriole amplification, expression of FoxJ1 and multicilogenesis341.   There is not 
a total loss, rather a reduction of MCCs in Myb-deficient animals346.  A working 
model is that Myb has an early role in multiciliogenesis, including a novel S-like 
phase in which centriole amplification can occur uncoupled from DNA synthesis, 
and that induction of later stages of ciliary biogenesis 
Taken together, Myb and Mcidas are thought to act in one pathway, with 
Mcidas acting downstream of Notch signaling, but upstream of Myb, to activate 
genes that drive multiple basal body formation and to switch on FoxJ1 to activate 
genes required for basal body docking, ciliary outgrowth and motility346,345,347.  
The Role of p73 in Development: Goals of this Dissertation 
 Transcription factors regulate a wide array of cellular processes.  To date, 
the mechanistic understanding of the p73 protein has primarily been focused on 
its role in tumorigenesis.  Like p53, the role of p73 in cell cycle regulation and 
apoptosis has been widely studied to determine if there is a possible treatment 
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angle for patients with intact p73 signalling to treat cancers.  Unlike p63, the role 
of p73 in development has been very minimally understood, with most focus on 
the development of the brain (due the phenotypic changes in mouse models in 
which p73 was ablated).  Our study further unifies the diverse phenotypic 
changes observed in the p73-/- mouse models under a single biological function 
of p73 in the regulation of MCC development1. 
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CHAPTER II 
MATERIALS AND METHODS 
CULTURED CELLS 
Cellular Growth Conditions 
The majority of the following cell lines were purchased from American 
Type Culture Collection (ATCC). BT549, DU4475, HCC1143, HCC1187, 
HCC1395, HCC1599, HCC1806, HCC1937, HCC38, and HCC70 were 
maintained in Roswell Park Memorial Institute (RPMI) 293FT, CAL120, CAL51, 
HCT116, H1299, HDQP1, HS578T, MDAMB157, MDAMB231 MDAMB436, 
MDAMB453, MDAMB468, RKO, SW527 maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Life Technologies, Carlsbad, CA).  BT20 and CAL851 
were maintained in DMEM supplemented 10% fetal bovine serum (FBS) (Gemini 
Biologicals, West Sacramento, CA) and sodium pyruvate (Life Technologies, 
Carlsbad, CA).  MCF10A were maintained in DMEM/F12 (Life Technologies, 
Carlsbad, CA) supplemented with horse serum (Gibco, Life Technologies, 
Carlsbad, CA), hEGF (Gibco, Life Technologies, Carlsbad, CA),  1.0 µg/ml 
hydrocortisone (Sigma-Aldrich, St. Louis, MO), 1 ng/ml cholera enterotoxin (ICN 
Biomedicals, Inc., Aurora, OH) and 1.0 µg/ml insulin (Novo Nordisk, Princeton, 
NJ).  CAL148 were maintained in DMEM supplemented with 20% FBS and 1 
µg/ml hEGF.  MFM223 were maintained in MEM (Earle’s Salts) (Life 
Technologies, Carlsbad, CA) supplemented with 15% FBS, insulin, apo-
transferrin (Sigma-Aldrich, St. Louis, MO), and 15 nM sodium selenite (Sigma-
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Aldrich, St. Louis, MO).   SUM149, SUM159, and SUM185 were maintained in 
F12 Ham’s (Life Technologies, Carlsbad, CA) supplemented with 5% FBS, 
insulin, and hydrocortisone. 
Human Mammary Epithelial Cells (HMECs) were isolated by Kimberly 
Johnson from normal breast tissue that was acquired in coordination with the 
Vanderbilt-Ingram Human Tissue Acquisition and Pathology Shared Research 
(TPSR).   The cells were cultured in DMEM/F12 medium 1:1 supplemented with 
1.0 µg/ml insulin, 1.0 µg/ml hydrocortisone, 10 µg/ml, 0.1 mM 
phosphoethanolamine (Sigma-Aldrich, St. Louis, MO), 2.0 beta-estradiol (Sigma-
Aldrich, St. Louis, MO), 10 nM 3,3’,5-triiodo-L-thyronine sodium salt (Sigma-
Aldrich, St. Louis, MO), 15 nM sodium selenite, 2.0 mM L-glutamine (Gibco, Life 
Technologies, Carlsbad, CA), 1% penicillin-streptomycin (Gibco, Life 
Technologies, Carlsbad, CA), 1 ng/ml cholera enterotoxin (ICN Biomedicals, Inc., 
Aurora, OH), 1% FBS  and 35 µg/ml BPE (Gibco, Life Technologies, Carlsbad, 
CA).  
Murine Tracheal Epithelial Cells (MTEC), whose harvest is described in a 
later section in full detail, were grown DMEM/F12 supplemented with [1M HEPES 
(Sigma-Aldrich, St. Louis, MO), 200 mM L-glutamine (Sigma-Aldrich, St. Louis, 
MO), 7.5% NaHCO3 (Sigma-Aldrich, St. Louis, MO), 1% penicillin-streptomycin 
(Gibco, Life Technologies, Carlsbad, CA),	 Fungizone (Life Technologies, 
Carlsbad, CA), 10 µg/ml Insulin (Novo Nordisk, Princeton, NJ), 5 µg/ml apo-
transferrin, 0.1 µg/ml cholera toxin (Sigma-Aldrich, St. Louis, MO),  25 ng/ml 
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hEGF, 0.03 mg/ml bovine pituitary extract (Gibco, Life Technologies, Carlsbad, 
CA), 5% and retinoic acid (Sigma-Aldrich, St. Louis, MO)]  
VA10, human bronchiole epithelial cells, were generously shared with us 
by the Thórarinn Guõjónsson group at the University of Iceland253. Cells were 
cultured in Bronchiole Epithelial Growth Media (BEGM) (Lonza Walkersville, Inc., 
Walkersville, MD) supplemented with single-quots of bovine pituitary extract 
(BPE), hydrocortisone, human epidermal growth factor (hEGF), epinephrine, apo-
transferrin, insulin, retinoic acid, triiodothyronine, and 1% penicillin-streptomycin 
all provided from Lonza Walkersville, Inc., Walkersville, MD.  VA10 cell line was 
passaged by trypsinizing cells for approximately 5 minutes at 37˚C, neutralizing 
trypsin with 0.5 mg/ml soybean trypsin inhibitor (Gibco, Life Technologies, 
Carlsbad, CA), centrifuging cells at 1500 RPM for eight minutes, and re-plating in 
their normal growth media. 
All medias were supplemented with 10% FBS (Life Technologies, 
Carlsbad, CA) and 1% penicillin-streptomycin (Gibco, Life Technologies, 
Carlsbad, CA) and trypsinized using 0.25% Trypsin at 37˚C unless otherwise 
noted.  
Lentiviral Generation of shRNA and Overexpression Vectors 
Lentiviral methods of RNAi-mediated knockdown or cDNA overexpression 
were utilized for the following dissertation work.  Lentiviral vectors were 
transfected with Lipofectamine 2000 (Invitrogen, Life Technologies, Carlsbad, 
CA) into 293FT cells along with 10 µg PAX2 and 10 µg pMD2 viral packaging 
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vectors.  Media containing lentiviral particles was harvested 48 hours after 
transfection filtered through 0.45 µM filters, and concentrated using Lenti-X 
concentrator (Clontech, Mountain View, CA).  Prior to infection of target cells 
polybrene (Sigma-Aldrich, St. Louis, MO) was added to the media at a final 
concentration of 6 µg/ml and incubated at room temperature for 15 minutes.  Viral 
media was immediately added to target cells and not frozen because it resulted 
in maximal shRNA knockdown. 
shRNA gene targeting:  The human pSicoR lentiviral system was utilized 
for knockdown of p7331,60,348,349.  The combination of TAp73-1 and TAp73-2 
shRNAs yielded the best knockdown of p73.  We also utilized Sigma-Aldrich 
Mission pLKO.5-puro shRNA system (Sigma-Aldrich, St. Louis, MO) for knock 
down of p73 in human and mouse cells.  TRCN0000272526, TRCN0000272527, 
and TRCN0000272587 yielded the greatest knockdown in human cells and 
TRCN0000430727 and TRCN0000012757 yielded the best results in MTECs.  24 
hours after infection, target cells transduced with Mission lentivirus were selected 
for by addition of puromycin at the concentration determined to have optimal 
effects at 48 h for each individual cell line.  
Exogenous Overexpression vectors:  p73 isoform specific exogenous 
overexpression experiments were conducted using pcDNA3 backbone constructs 
that were kindly provided by Backendorf and Melino79,350.  Yeast two-hybrid 
candidate interacting proteins were cloned into 3xFLAG cDNA vector (Sigma-
Aldrich, St.  Louis, MO).  Transfection was performed using Lipofectamine in 
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H1299 and 293 cells (Invitrogen, Life Technologies, Carlsbad, CA).  FoxJ1 
lentiviral overexpression cDNA vector (Thermo Scientific, Waltham, MA) was 
used to express full length FoxJ1 by viral production in 293FT and further 
infection of target cells.  Cells were lysed for immunoprecipitation, RNA analysis, 
and immunoblot 24-48 hours after transfection. 
Protein Harvest  
Cells were trypsinized, pelleted, and washed with ice-cold phosphate-
buffer saline.  Depending upon the downstream uses for the protein lysate cells 
were lysed with radio immunoprecipitation assay (RIPA) buffer [150 mM NaCl, 
1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris [pH 8.0], 5 mM 39 
EDTA] or EBC lysis buffer [50mM Tris pH 7.5, 100mM NaCl, 0.5% NP40].  Lysis 
buffers were supplemented with phosphatase inhibitors [50 mM NaF, 0.2 mM 
NaVanadate, 10 mM p-nitrophenyl phosphate] and protease inhibitors [antipain 
(10 mg/ml), leupeptin (10 mg/ml), pepstatin A (10 mg/ml), chymostatin (10 
mg/ml) (Sigma-Aldrich, St. Louis, MO), 4-(2-aminoethyl)-benzenesulfonylfluoride 
(200 mg/ml) (Merck, EMD Millipore, Darmstadt)].  Cells were incubated in lysis 
buffer for 30 minutes total and vortexed for 10 seconds every ten minutes for a 
total of 3 vortex cycles.  The lysate was centrifuged at 13,500 RPM for 15 
minutes at 4°C and the supernatant was collected.  Protein levels were 
determined using the Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc., 
Hercules, CA) kit and the lysates were stored at -80. 
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Immunoblot Analysis 
Protein lysate was boiled in 1x Laemmli sample buffer for five minutes and 
then separated using SDS polyacrylamide gel electrophoresis (SDS-PAGE). 
Proteins were transferred to Immobilon-P membranes (Millipore, Billerica, MA) 
using the Transblot Turbo (Bio-Rad Laboratories, Inc., Hercules, CA) system.  
Membranes were blocked in 5% nonfat dry milk dissolved in TTBS (100mM Tris-
HCL pH 7.5, 150mM NaCl, 0.1% Tween-20) for one hour at room temperature 
and incubated in primary antibody overnight at 4˚C.  All antibodies used in 
immunoblot analysis and the concentrations at which they were used can be 
found in Table 1.  All immunoblots were washed in TTBS (50 mM Tris, 150 mM 
NaCl, and 0.05% Tween 20 pH 7.6) washes and incubated for an hour in HRP-
conjugated secondary antibodies.  After this incubation the immunoblots  were 
rocked in three successive ten minute TTBS washes.  Finally, enhanced 
chemiluminescence (ECL) reagent for film exposure was used for visualization of 
protein expression levels.   
Immunoprecipitation  
 
Co-immunoprecipitation (co-IP) of p73 with possible binding partners was 
performed following cellular protein lysis using EBC Buffer [120 mM NaCl, 0.5 
(v/v) Nonidet P-40, 5 µg/ml leupeptin, 10 µg/ml aprotinin, 50 mM Tris-Cl (pH8.0] 
supplemented with phosphatase inhibitors and protease inhibitors as above. 
Protein G Dynabeads (ThermoFisher Scientific, Waltham, MA) were incubated 
with 0.5-1 mg of protein from cellular lysates for one to two hours.  After this pre- 
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Table 1. Antibodies Used in the Study of p73 and its Biological Roles.  
Antibody epitope target is listed along with the catalog number and company 
purchased from. Western blot analysis and/or immunoflourescence experiments 
were conducted using the antibody at the dilution indicated in the table in either 
2% milk (Western blot) or 5% goat serum (immunofloursecence).  Antibodies 
utilized for immunoprecipitation have been annotated in the above table.  Each of 
the antibodies are further categorized by the biological function. 
  
Epitope Alt. Name/ Catalog no.  Company Species Western Immunoflourescence
IP/ChIP 
validated
p73 EP436Y Epitomics/Abcam Rabbit 1 to 500 1 to 1,200**  Y
p73 A300-126A-2 Bethyl Rabbit 1 to 1,000 Y
p73 IMG-246 Imgenex Rabbit 1 to 200
p73 IMG-259 Imgenex Rabbit 1 to 200
p63 4A4 Santa Cruz Rabbit 1 to 1,000
p63 H129 Santa Cruz Rabbit 1 to 500 1 to 40 and/or 1 to 1,000 ** Y
p53 DO1 Santa Cruz Mouse 1 to 1,000
Uteroglobin Ab40873 Abcam Rabbit 1 to 140,000**
PGP9.5 Ab8189 Abcam Rabbit 1 to 750
FoxJ1 14-9965 eBiosciences Mouse 1 to 200**
FoxJ1 Sc-517 Santa Cruz Mouse 1 to 200
C-MYB C-19 Santa Cruz Rabbit 1 to 1,000**
acetelated Alpha tubulin 6-11B-1 Sigma Aldrich Mouse 1 to 50,000
Traf3ip1 Rabbit 1:3000**
Gamma tubulin H-183 Santa Cruz Rabbit 1 to 2,000**
Cytokeratin 5 20R-CP003 Fitzgerald Guenia Pig 1 to 200
Keratin 14 30R-2140 Fitzgerald Guenia Pig 1 to 200
p21 F5 (sc-6246) Santa Cruz Mouse 1 to 300
p21 556430 BD Mouse 1 to 300
MDM2 Ab1 Calbiochem Mouse 1 to 250
MDM2 Smp14 Santa Cruz Mouse 1 to 200
puma 4976 Cell Signalling Rabbit 1 to 500
Noxa 114C307 Calbiochem Mouse 1 to 250
PARP 9542 Cell Signalling Rabbit 1 to 500
Actin A5316 Sigma Aldrich Mouse 1 to 10,000
Ki-67 550609 BD Pharmagen Mouse 1 to 1,000**
FLAG F3165 Sigma Aldrich Mouse 1 to 500 Y
Tab2 C88H10 Cell Signalling Rabbit 1 to 500
TAB2 A302-759A Bethyl Rabbit 1 to 500
TAK 3456-1 Epitomics Rabbit 1 to 500
EPN1 h-130 (sc-25521) Santa Cruz Rabbit 1 to 300
EPN2 c-16 (sc-5414) Santa Cruz mouse 1 to 500
NEDD4-2 46521 Abcam Rabbit 1 to 1,000
RSL1D1 SAB1400486 Sigma Aldrich Mouse 1 to 500
ITCH H-110 Santa Cruz Rabbit 1 to 200
iASPP A4605 Sigma Aldrich Rabbit 1 to 1,000
iASPP ab34898 Abcam Rabbit 1 to 500
WWP2 N-15 (sc-11896) Santa Cruz Goat 1 to 500
WWP1 K-20 (sc-11894) santacruz Goat 1 to 500
Alexaflour 488 G anti M Goat N/A 1 to 200
Alexaflour 594 G anti M Goat N/A 1 to 200
Alexaflour 488 G anti R Goat N/A 1 to 200
Alexaflour 594 G anti R Goat N/A 1 to 200
Alexaflour 488 G anti GP Goat N/A 1 to 200
Alexaflour 594 G anti GP Goat N/A 1 to 200
HRP G anti M Goat 1 to 10,000 1 to 1,000**
HRP G anti R Goat 1 to 10,000 1 to 1,000**
Antibodies Utlized For the Study of p73
Secondary 
Antibodies
p53 Family 
Antibodies
Lung Markers 
and Proteins
Downstream 
Targets of p53 
Family
Co-associated 
Proteins            
(Yeast two-
Hybrid)
Biological 
Readout 
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clearing of the lysate, a slurry of beads complexed with optimized antibody of 
interest (in general 1-3 µg antibody was added to 1 mg IP) was added to the 
lysate and incubated for 2-4 hours with end-over-end rotation at 4˚C.  The beads 
were washed (via magnetic separation) a total of four times 10 minutes each in 
respective cell lysis buffer utilized for each cell type.  Lamilli sample loading 
buffer was added to the bead, antibody, co-IP mixture.  These samples were then 
incubated at 95˚C for six minutes and analyzed by Western analysis. 
mRNA Isolation and Expression Analysis by qRT-PCR:  
RNA was harvested from cells using the Aurum Total RNA Mini kit (Bio-
Rad Laboratories, Inc., Hercules, CA).  Cells were needle passaged 25 times 
through a 23-gauge needle in the enclosed lysis buffer to ensure complete lysis 
of cells for mRNA harvest.  Samples were incubated with DNase for 30 minutes 
at room temperature directly on the column during RNA purification 
cDNA was generated from total RNA using the TaqMan Reverse 
Transcription kit (Applied Biosystems, Roche, Basel, Switzerland).  A total of 750 
ng of RNA was added to each reaction and resultant cDNA was diluted 1:5 
before conducting qRT-PCR.  qRT-PCR was conducted using an iCycler (Bio-
Rad Laboratories, Inc., Hercules, CA) instrument and the iQ SYBR Green 
Supermix (Bio-Rad Laboratories, Inc., Hercules, CA).  Primers for genes of 
interest were designed using Primer-3 software351 or manually.  All primers that 
were utilized for this dissertation work can be found in Table 2.  A standard curve 
and melting curve analysis was conducted for each qRT-PCR to assess PCR 
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Table 2. Primers Used for the Study of p73 and its Biological Roles.  The 
primer target is listed along with the sequence of the primer itself.  Checkmarks 
annotate the species (human and/or mouse) to which the primers were designed 
target.  
 
 
 
Primer Name Sequence Human Mouse Primer Name Sequence Human Mouse
p73-Exon 5 For GACATGCCCCATCCAGATCA Puma For 2 CCACCACCATCTCAGGAAAG ---
p73- Exon 5 Rev AGCTCGTGGTTGGGGCAGCG Puma Rev 2 ACGTTTGGCTCATTTGCTCT ---
p73-Exon 6-7 For GTGGATGACCCTGTCACCGG Puma For 3 TGAGCCAAACGTGACCACTA ---
p73-Exon 6-7 Rev GAAGTTGTACAGGATGGTGG Puma Rev 3 GCAGAGCACAGGATTCACAG ---
p73-Exon 10 For GGAGCTTGTGCCCCAGCCTTTG Noxa For CCGTGTGTAGTTGGCATCTC ---
p73-Exon 10 Rev GGTGACTCGGCCTCTGTAGG Noxa Rev CCCACTCAGCGACAGAGC ---
FoxJ1 For 1.2 TGACAGCCTGACCAGCCTGC p53 For GCCAAGGGAGGGAAAAGG ---
Foxj1 Rev 1 TGGTGGTAGCCGTGGGGGTC p53 Rev CTCTAACTAGGCTCAGGCTACC ---
Cdc20b For 2 CTGGTCTTCGAAATGACTAC Jag1 For 1 CAACCGTGCCGTGACTATTTCTGC ---
Cdc20b Rev 2 ACTTCTCCCTCGCTGGTGCC Jag1 Rev 1 TGTTCCCGTGAAGCCTTTGTTACAG ---
Mcin For 3 CTGGATAAGCTGATGATCAC p73 L TGCGACATCTTTTGGTTCTG ---
Mcin Rev 3 GGATGGCGTCCACTTCCGCG p73 R GTCCCAAGTCCAGCAGAGAG ---
Dll1 For 3 TTCCCCTGGGTGGCCGTGTG Foxj1 L2 AAGCCTCCCTACTCGTATGC ---
Dll1 Rev 3 CGGACGCGACCACCACAGC Foxj1 R2 GCAGCCGTTGTCCGTGATCC ---
E2f5 For 1 CTGGATCTCAAAGCGGCTGC Traf3ip1 L2 TGGTTGTAATGGTGTCGGGA ---
E2f5 Rev 1 CAATTCCCTCTAAGACATTG Traf3ip1 R2 ACCGCATCGTCACTAGAGAG ---
Notch1 For 5 GGCTTCACGGGCAGCTACTG Stk33 L CGGTATTTGGGGTGGTCTC ---
Notch1 Rev 5 GCACAAGGTTCTGGCAGTTG Stk33 R AGGTCCCCACAGTAAGTTCG ---
Notch3 For 3 GGCGTGGGCTCCTTTTCCTG Myb L3 GACTTTGAGATGTGTGACCATGA ---
Notch3 Rev 3 CGGTGAAGGAGGCCACGTG Myb R3 CTTTCCAGTCATCTGTTCCATTC ---
Mdm2 For 3 TTTCCTTAGCTGACTATTGG Cct4 L TGCTTTGCAGATGCTATGG ---
Mdm2 Rev 3 TGAGTTTTCCAGTTTGGCTT Cct4 R GGACAACCAGTTCCTCCAAA ---
Rrad For 1 TTCATTGAGACATCAGCGGC Spag16 L ACGACGGGGAGATTCTCTT ---
Rrad Rev 1 GTGGCAGGACTTGGATTTGG Spag 16 R ACCTGCTGGCACATTTAACC ---
Dnaili For1 CGGGCGGTCACCATCAACTG Dvl3 L GAGGCTGAGGCACAAGAATC ---
Dnail1 Rev 1 TGCAGTGCCTTCCTCATGCC Dvl3 R GCAGGCAAGATTGAGTCACA ---
Ppp1cc For 2 GACCAACTGATGTACCAGATC Mink1 L AAGAAGCGGGGTGAGAAAGA ---
Ppp1cc Rev 2 CCAAATGTGAAGGACACTCC Mink1 R CAGGCACGTTCATGATGGAG ---
Ccp110 For 2 GTTAGCTTTTGAAGAAATGCG Cp110 L2 TGACTGTGGGAAGATGGAGG ---
Ccp110 Rev 2 CTCCTGCTCTTCTATTTCCTT Cp110 R2 GCCACTCCATGAAAGCGAA ---
Gmnn For2 AAGAAATTGAACAAAAGGAC Rbl2 L3 AGATCTCTCTTGGCCTGCTG ---
Gmnn Rev  1.2.3 CTTCAGAATCAAATTCCTGA Rbl2 R3 ACACCTCTCTACAAAGGCC ---
Mdm2 For CCCCTTCCATCACATTGC --- E2f4 L TCCTCATGAGTGACGTAGGC ---
Mdm2 Rev TTACAATCAGGAACATCAAAGC --- E2F4 R CGGGCGCAAGAACTAGACGA ---
Cdkn1a For CCTTGGCCTGCCCAAGC --- Lztfk L2 TCTGCAGAGTTGGGCCTAAA ---
Cdkn1a Rev CTTGGAGAAGATCAGCCG --- Lztfk R2 AGCCTCTCTTTGAACGAGCA ---
Gapdh For CATGTTCCAATATGATTCC --- B-actin For GTTTGAGACCTTCAACACCC ---
Gapdh Rev CCTGGAAGATGGTGATG --- B-actin Rev CATTGCCAATGGTGATGACC ---
p73-For 2 ACTTTCCAGCAGTCCAGCAC --- Gapdh For AGGTCGGTGTGAACGGATTT ---
p73-Rev 2 GGACACCTTGATCTGGATGG --- Gapdh Rev GGGGTCGTTGATGGCAACA ---
p73-For 3 GTCAGCCACCTGGACGTACT --- Gapdh For CATGGCCTTCCGTGTTCCTA ---
p73-Rev 3 GGAGCAGACTGTCCTTCGTT --- Gapdh Rev CCTGCTTCACCACCTTCTTGAT ---
Primer Sequences Utlized for the Study of p73 Primer Sequences Utlized for the Study of p73
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efficiency, purity, and quality of the final products.  The cycling conditions used 
were: 95°C for 3 minutes, 40 cycles of 95°C for 10 seconds with annealing 
temperatures between 55-62°C (proper primer specific annealing temperatures 
were determined before experimental usage).  
 
MURINE MODEL 
Generation of p73 Knockout Mice 
The generation of a mouse model with a conditional p73 allele is illustrated 
in Figure 3.  A vector targeting p73 exons 7, 8, and 9 was made using BAC 
recombineering vectors and methods352.  The targeting vector was electroporated 
in 129S6 mouse ES cells and neomycin resistant clones were screened by 
southern blot hybridization (Figure 3).  Male chimeric mice made by the 
microinjection of clone 2A7 into blastocysts isolated from C57Bl6 mice were bred 
to C57/Bl6 females mice for detection of germline transmission of the p73 allele 
referred to as p73floxE7-9N.  The FRT-flanked neomycin resistance gene was 
removed by crossing to a global FlpE ‘deleter’ mouse353 line to derive mice with 
p73floxE7-9 allele.  For the experiments described herein, we globally deleted 
exons 7-9 by crossing p73floxE7-9 to a BALB/c-Tg (CMV-Cre)1Cgn/J then 
interbreeding to obtain p73+/+, p73+/- and p73-/- animals.  All procedures were 
conducted in compliance with NIH guidelines and following IACUC approved 
protocols.  The experiments presented occurred in mixed strain mice, however 
we have confirmed the lack of ciliated cells in BALB/c congenic p73-/- mice. 
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Figure 3. Generation of the p73floxE7-9 Mice. Schematic representation of the targeting strategy 
used to conditionally delete exons 7, 8, and 9 of p73. Red triangles denote the introduced loxP 
sites. Black circles represent Frt sites utilized to remove the neomycin resistance cassette (NeoR) 
(orange box) by crossing with a FlpE deleter mouse. The red rectangle marks the location of an 
exon 14 Southern probe for identification of recombinant clones in combination with Cla1 and HindII 
restriction enzymes. A second probe located outside the long DNA homology arm that was used to 
screen the mESCs. Clone 2A7 (**) had germline transmission leading to the mice utilized for this 
study. Mouse targeting strategy was designed by Mark Magnuson, Jennifer Rosenbluth, and Lucy 
Tang. Southern blot was generated by Deborah Mays. 	
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Murine Tissue Harvest  
Animals were sacrificed following all Institutional Animal Care and Use 
Committee (IACUC) approved methods.  Mice were overdosed using isoflurane 
and the tissues of interest were removed for analysis following cervical 
dislocation.  Tissues that were utilized for further analysis by H&E or 
immunofluorescence were fixed in cassettes submerged in 10% neutral buffered 
formalin (NBF) (EMB Chemicals, Gibbstown, NJ) overnight.  After overnight 
fixation the samples were delivered to Vanderbilt University Translational 
Pathology Shared Resource (TPSR) for further processing and paraffin 
embedding.  Tissue utilized for protein or RNA were immediately flash frozen in 
liquid N2 upon removal from the animal.  
Histological Staining of Murine Tissue 
Alcian Blue: Unstained paraffin embedded tissues were de-paraffinized 
and re-hydrated through xylene and successive alcohol washes.  The mucins 
were stained with 1% alcian blue solution at pH 2.5 for 30 minutes at room 
temperature as previously described354.  The nuclei of these sections were then 
counterstained with nuclear fast red for five minutes.  The slides were then 
dehydrated and coversliped using xylene-based Cytoseal (Thermo Scientific, 
Waltham, MA).  
Hemotoxylin and Eosin (H&E):  Unstained paraffin sections of tissue were 
rehydrated and stained for 5 minutes using modified Mayer’s hematoxylin 
(Richard-Allen Scientific, Thermo Scientific, Waltham, MA).  Tissue sections were 
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washed thoroughly to remove any remaining stain and then stained using Eosin 
Y (Richard-Allen Scientific, Thermo Scientific, Waltham, MA) for 1 minute.  Cells 
were then dehydrated and coverslipped using xylene-based Cytoseal. 
Immunofluorescence  
De-paraffinization and rehydration of tissue sections was followed by 
antigen retrieval using citra buffer and heating.  Tissue was permeablized using 
0.1% Tween 20 in PBS.  The tissue sections were blocked with 5% goat serum 
and 0.3% Triton X in PBS for one hour at room temperature.  Some of the 
antibodies listed in Table 1 required amplification of signal in order to observe 
positive immunofluorescence (**).  For those tissues that were stained with an 
amplification step, endogenous HRP background was quenched by processing 
the tissue through a three percent hydrogen peroxide solution for at least five 
minutes.  Tissues were all blocked using Image-it Enhancer (Life Technologies, 
Carlsbad, CA) for 30 minutes at room temperature, and if the sections were to be 
stained with antibodies generated in mice the section was incubated in M.O.M 
block (Vector, Golden, CO) at room temperature for one hour.  Primary 
antibodies were incubated on respective tissues overnight at 4˚C.  We used 
either fluorescently labeled secondary AlexaFlour (Life Technologies, Carlsbad, 
CA) or CY3/FITC TSA amplification kit (Perkin Elmer, Waltham, MA) for 
visualization of immunoflourescence.  For TSA amplification we utilized HRP-
conjugated secondary antibodies commonly used in Western blotting to bind to 
the respective primaries that require amplification.  After one hour of incubation in 
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secondary the tissue was incubated for eight minutes using CY3/FITC diluted 
1:50 in dilution buffer for eight minutes.  After this incubation tissue was washed 
and cover slipped using SlowFade Gold with DAPI (4’6-diamidino-2-phenylindole) 
(Life Technologies, Carlsbad, CA). 
MTECs were processed in a similar manner as the tissue sections stained 
by immunofluorescence except that the cells were fixed using four percent 
paraformaldehyde (PFA) for 10 minutes. 
Image Capture and quantification: All images were captured using Leica 
DM IL LED microscope (Leica, Solms, Germany) and qCapturePro 6.0 software 
paired with a QiCam Fast1394 (QImiging, Burnaby, BC, Canada).  
Immunofluorescence images were quantified using ImageJ software. 
Tissue Protein Harvest 
Tissue was placed in RIPA buffer containing the phosphatase and 
protease inhibitors listed in the protein harvest section above.  The tissue was 
homogenized on ice for one minute with care to ensure that the sample did not 
go through a period of foaming which results in loss of protein yield.  After 
homogenization the tissue was incubated on ice for 30 minutes, and were 
vortexed for 10 seconds every ten minutes for a total of 3 vortex cycles.  The 
samples were pelleted at 4˚C by centrifugation at 13,500 rpm for 15 minutes. 
Immunoblot analysis of protein was performed as described above. 
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Tissue mRNA Isolation and Quantification: 
 Flash frozen tissue was weighed and appropriate amount of trizol was 
added to the tissue (1 ml TRIzol per 50-200 mg tissue).  The tissue was 
homogenized for 1 minute using a hand-held homogenizer, and chloroform was 
used to separate the RNA from the rest of the lysate.  The RNA was then column 
purified using the Aurum Total RNA mini-kit in the mRNA isolation and 
expression analysis by qRT-PCR section above.  cDNA preparation and qRT-
PCR was completed as described above. 
Murine Tracheal Epithelial Cell (MTEC) Isolation 
Mice were euthanized following IACUC guidelines and the entire mouse 
was rinsed with ethanol in order to best sterilize the animal and reduce the 
amount of hair that will carry over into the cell culturing system.  Tracheas were 
removed from above the larynx to the bifurcation of the trachea and placed in 
Ham’s F12 (Gibco, Life Technologies, Carlsbad, CA) media.  They were then 
cleaned of any excess tissue in a laminar flow hood, and the tracheas were cut 
lengthwise to expose the inner tracheal epithelium.  The tracheas washed three 
times with Ham’s F12 [supplemented with 0.002% Gentamicin (Life 
Technologies, Carlsbad, CA), 0.001% Fungizone (Life Technologies, Carlsbad, 
CA), and 1% Penicillin-Streptomycin], and placed in a 0.15% protease from 
Streptomyces grisseus (Sigma-Aldrich, St. Louis, MO) solution (1 ml protease per 
trachea) for an overnight incubation at 4˚C.  
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Tracheas were inverted 20-25 times after the overnight incubation and 
then further incubated for one hour at 4°C.   After the overnight protease 
incubation epithelial cells were isolated from the tracheas by washing them three 
times with Ham’s F12 supplemented with twenty percent FBS in order to 
inactivate any protease before culturing the subsequent epithelium.  After the 
three washes the remaining tracheal tissue was discarded and the supernatant 
containing the epithelial cells was pelleted at 1400 RPM for 10 minutes at 4˚C.  
Cells were then suspended in DNase solution (100 µL per mouse trachea) and 
incubated at room temperature for ten minutes.  Fibroblasts were selected 
against in MTEC cultures by culturing the cells for four hours in PRIMARIA 
coated tissue culture dishes (Falcon, Thermo Fisher Scientific, Waltham, MA) (up 
to 15 tracheas per dish).  After the separation of loosely adherent fibroblasts from 
the non-adherent epithelial cells the MTECs can be grown on collagen coated 
plates and transwells for differentiation.   
Air Liquid Interface (ALI) Differentiation 
MTECs have been utilized to recapitulate the developing mouse airway 
epithelium in a transwell organotypic culturing system.  Cell isolation and 
methods for differentiation355,356 of these cultures in an organotypic submerged 
culture or at an air liquid interface (ALI) were utilized have been previously 
reported253,254.  Transwells were coated with collagen using 4.1 mg/ml rat-tail 
collagen (Gibco, Life Technologies, Carlsbad, CA) mixed with 0.02 N acetic acid.  
Plates or transwells were collagen coated overnight at 37˚C by adding 1 ml 
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collagen to each 12-well transwell or a 24-well plate.  After overnight incubation 
the remaining liquid was removed from the well and allowed to dry.  PBS was 
used to wash the collagen-coated wells three times and then the plates were 
allowed to dry before plating of the cells.  
MTEC were seeded at a density to reach 100% confluent within two to 
three days of growth on the collagen-coated well and maintained in MTEC Plus 
Growth Media (Gibco, Life Technologies, Carlsbad, CA) for approximately five 
days.  After the cells reached 100% confluency, the cells were stimulated to 
differentiate by removing the media above the transwells (generating an air 
interface) and adding MTEC differentiation media [MTEC Plus Growth Media 
supplemented with 2% NuSerum (Sigma-Aldrich, St. Louis, MO) and Retinoic 
Acid (Sigma-Aldrich, St. Louis, MO)] to the lower chamber of the transwell.  Cells 
were fed every 48 hours during the period of differentiation (generally a fully 
differentiated epithelium is evident by day 14-16).   
Immediate ex vivo Murine Tracheal Crosslinking and ChIP-seq  
Immediate ex vivo epithelial cell harvest and crosslinking: For each of the 
individual chromatin immunopreciptation (ChIP) experiments utilizing mouse 
tracheal epithelial cells in this dissertation work 50 animals (~50 million tracheal 
epithelial cells) were combined per ChIP condition.  The crosslinking and cellular 
processing took place immediately following sacrifice without freezing in 
between.  Following IACUC approved guidelines mice were sacrificed and the 
tracheas of the animals were removed within 60 seconds of death.  Tracheas 
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were removed as cleanly as possible while retaining the larynx.  After the trachea 
was removed from the organism it was opened lengthwise using small scissors 
and proteins were cross-linked with 1 ml of 1% formaldehyde for eight minutes.  
Of note the tissue turns more opaque and white throughout the crosslinking 
protocol.  After the eight minute incubation in formaldehyde the crosslinking was 
quenched by adding glycine (Thermo Fisher Scientific, Waltham, MA) to a final 
concentration of 0.125 M.  The trachea was incubated in the 
formaldehyde/glycine mixture for two to five minutes. 
After quenching of the crosslinking reaction the tracheas were stored on 
ice in PBS + complete protease inhibitor (CPI) (Roche, Basel Switzerland) to 
protect from degradation.  All 50 tracheas were scraped one at a time into 1ml of 
RIPA + CPI.  After scraping the tracheas they were placed back in PBS + CPI on 
ice.  At the end of tracheal scraping, trachea PBS/CPI mixture was slightly 
vortexed and the leftover tracheas were removed.   The mixture was centrifuged 
at 2000 RPM for ten minutes in order to collect any residual epithelial cells that 
were missed during scraping, and the pelleted cells were added to the RIPA 
buffer used for scraping.  Once all of the tracheal epithelial cells were combined 
into the RIPA + CPI, the solution was vortexed every 15 minutes for a total 45 
minutes of lysis.   
Human cell line crosslinking: Human cell line ChIP-seq was also 
conducted with 50 million cells alongside the scraped tracheal cells as a control 
for experimental methods.  HCC1806 and HMEC lines were grown to 70% 
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confluency and prior to crosslinking they were washed once with PBS.  Cells 
were cross-linked with 30 ml of 1% formaldehyde (Thermo Fisher Scientific, 
Waltham, MA) was added to each 15 cm dish (Sarstedt Nümbrecht, Germany) 
and the cells were incubated at room temperature for 10 minutes.  The 
crosslinking process was quenched by adding glycine as discussed above.  The 
cells were then scraped from the plate into ice-cold PBS/CPI, pelleted at 2000 
RPM for 5 minutes at 4˚C, and then re-suspended for sonication. 
Sonication:  All sonication procedures were conducted on ice and at 4˚C. 
A Biorupter (Diagnode, Denville, NJ) sonicator was used to shear genomic DNA 
to fragments averaging 300bp in size.  To prevent warming of the samples, the 
Biorupter probes and water tank was refilled with ice-cold water after each 
session of sonication.  All samples were processed as pairs and sonicated for 20 
minutes on the high setting with 30 second on 30 second off cycles.  The 
Biorupter water bath was cooled after the first 10 minute sonication. After 
completing sonication of each sample, nuclear and cellular debris were pelleted 
by centrifugation at 14,000 RPM at 4°C.  The supernatant of each sample was 
collected.  50 µL of each sample was checked by agarose gel electrophoresis to 
verify proper sonication.  
ChIP:  The p73, p63, and Pol II antibodies that were optimized for ChIP 
using Protein G Dynabeads (Invitrogen, Life Technologies, Carlsbad, CA).  For 
each ChIP, 90 µL of bead slurry was washed using blocking buffer [1xPBS, 0.5% 
Tween20, 0.5% BSA] + CPI for 30 minutes.  The respective antibodies that were 
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to be used in the ChIP were then coupled to the magnetic beads for three hours 
by adding 30 µg of the antibody to the beads in 500 µL of cold blocking 
buffer/CPI.  Each sonicated sample of 50 million cells was added to the 
antibody/bead mixture and rotated end-over-end for 2-4 hours at 4˚C. 
After the four hour incubation the samples were washed four times with 
RIPA and four times with IP wash buffer [100mM Tris pH 8.5, 500 mM LiCl, 1% 
NP40, 1% deoxycholic acid] + CPI.   The ChIP beads were then resuspended in 
ChIP elution buffer [25mM Tris pH 7.5, 2mM EDTA, 200mM NaCl, and 0.5% 
SDS] and incubated at 65˚C for fifteen minutes with intermittent vortexing.  For 
optimal elution the first eluate was saved and a second elution was conducted 
following the same steps as above, and both elusions were combined before 
purification of enriched DNA.  
DNA purification and Library generation:  Proteinase K was used to digest 
the proteins that were attached to the sonicated DNA overnight at 56˚C.  We then 
used phenol-chloroform extraction followed by ethanol precipitation to purify the 
DNA.   To each of the DNA sheared samples we added 200 µl of phenol 
chloroform (pH 8.0) and vortexed to adequately mix the sample.  They were then 
centrifuged on full speed for 5 minutes.  The aqueous top layer was removed to a 
clean tube avoiding touching any of the lower separated phases of liquid.  We 
then added 150 µl of 10 mM Tris (pH 8.3) and again the samples were vortexed 
to mix then centrifuged for 5 minutes at top speed.  The uppermost aqueous 
phase was combined with the earlier separated fraction.  Ethanol was added (2.5 
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volumes) as well as 0.1 volume of 3 M NaAc and 3  µl of glycogen to the phenol 
chloroform separated samples.  These samples were centrifuged at top speed at 
room temperature for 45 minutes.  The aqueous solution was then removed from 
the precipitated DNA pellet and the samples were dried.  The DNA was re-
suspended in 30 µl of water.	
The protocol used to generate libraries was a modification of standard 
Illumina protocols.  After DNA was purified we initially polished the ends of the 
sonicated fragments to make sure that the ends were filled and optimal for later 
steps of library generation (polishing).  Sonication of chromatin generally 
produces 5’ phosphates; however, in order to aid in the efficiency of the library 
generation we utilized a kinase step that ensures that all of the chromatin 
possesses 5’ phosphates (kinase).  The next step in library generation was to 
add a single adenosine nucleotide to the 3’ end of DNA (A-tailing), which aids in 
the ligation of indexes.  In our modified protocol, the index sequence used to 
identify each sample after next generation sequencing (NGS) was included in the 
adapters used for library preparation thereby allowing a single ligation step 
(ligation).  
Many library generation protocols utilize purification steps between the 
polishing, kinase, and A-tailing steps.  However, since the amount of DNA 
isolated from our protocol was very low, we conducted a single purification step 
after ligation.  We used AMPure beads (Agilent Technologies, Santa Clara, CA) 
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that bind to ChIP DNA of select size but not to any residual larger oligos 
remaining in the sample to purify the DNA fragments of interest.   
After our ChIP DNA was purified the samples were PCR amplified (18 
cycles [98˚C 20 sec., 52˚C 1 min., 72˚C 1 min.] to generate sufficient DNA for 
NGS.  The PCR reaction was gel purified (Qiagen Gel Extraction kit) from an 
agarose gel that was run long enough to separate 100-500 bp fragments the 
PCR libraries from any primer dimers or primers that remained in the samples as 
well as fragments that were much longer.  All three ChIP-seq experiments were 
conducted in duplicate.  Input DNA was harvested from the pooled trachea 
samples that cross-linked and sonicated, but did not undergo 
immunoprecipitation to serve as a comparison control for systematic bias. 
ChIP-seq Data Analysis 
Twenty to fifty million single-end 50 bp reads were generated for each 
ChIP-seq library using the Illumina HiSeq platform.  Reads were trimmed to 
remove adapters sequences with Flexbar v2.4357, aligned to GRCm38 using 
BWA-backtrack v0.6.1358 with default parameters, and filtered to remove reads 
with mapping qualities less than 30.  MACS2 v2.0.10.20131216359 was used to 
identify sites of genomic binding with default parameters and a q-value threshold 
of 0.05 using an input control.  MACS2 binding sites were filtered to remove 
mouse ENCODE blacklisted regions360 and mitochondrial DNA sites.  Annotation 
of binding sites with the nearest GENCODE M7 comprehensive TSS and overlap 
with genomic features was performed using Homer361 v4.7.  Motif analysis was 
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conducted using the GLAM2362 command line tool.  Correlation of read counts 
between ChIP-seq samples at sites of p63, p73, or Pol II genomic binding was 
performed with the deepTools bamCorrelate command line tool363.  The read 
alignments of ChIP-seq samples were 1X depth of coverage normalized for 
display in IGV using deepTools363 bamCoverage command line tool.  To analyze 
the overlap between our p73 ChIP-seq and the cilia-associated gene list364, we 
restricted our analysis to those genes shared between the different annotation 
methods used between the two studies. 
Scraped Murine Tracheal RNA Harvest, qRT-PCR, and Sanger Sequencing 
RNA was harvested from tissue by scraping the epithelium of the trachea 
in TRIzol and purified using the Aurum Total RNA Mini kit (Bio-Rad).  qRT-PCR 
experiments were conducted using oligo(dT)-mediated first-strand synthesis and 
SYBR Green (Bio-Rad) quantification.  mRNA levels were quantified using 
primers targeting exon 5, the exon 6/7 junction,  and exon 10 of p73 (Table 2).  
Sanger sequencing was conducted using identical primers. 
MTEC Exogenous Expression and RNA Harvest 
MTECs were isolated, cultured, and differentiated as previously described.  
MTECs harvested from p73+/+ and p73-/- mice were infected twice (at time of 
plating and 12 h later) with TAp73β and FG12-CMV control expression vectors 
as described previously31,60.  For Fig. 17, MTECs were grown as submerged 
cultures on collagen-coated plates for 3 d in MTEC growth media (DMEM/F12 
supplemented with HEPES, L-glutamine, NaHCO3, penicillin-streptomycin, 
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fungizone, insulin, apo-transferrin, cholera toxin, EGF, bovine pituitary extract 
and FBS).  For Fig. 16 and Fig. 17, MTECs were grown as submerged cultures 
on collagen-coated plates for 3 d in DMEM and then switched to differentiation 
media containing 2% NuSerum for 3 d 355,356.  For Fig. 15, MTECs were grown in 
transwells containing MTEC growth media for 5 days and then lifted to air-liquid 
interface for 24 h in differentiation media, followed by RNA harvest using the 
Aurum Total RNA Mini kit (Bio-Rad). 
shRNA-Mediated Gene Knockdown in MTECs 
 shRNAs directed to the 3’ untranslated region (shRNA 1- 
GAACTGCCCTTAGCTACATAT) and exon 6 (shRNA 2- 
AGTGTGGTTGTGCCGTATG) of p73 were purchased from Sigma Aldrich.  
MISSION TRC2 Non-Mammalian shRNA (Sigma Aldrich) was used as a negative 
control.  Viral production and transduction was performed as described above in 
the cell culture section.   For knockdown within the harvested MTEC cultures we 
determined that optimal gene knockdown was obtained by plating the MTEC cells 
in viral media that was concentrated using the Lenti-X Concentrator (Takara, 
Clontech, Mountain View, CA).  The cells were treated 16 h with lentivirus and a 
second infection was conducted by refreshing the cells with viral media for 8 h. 
RNA-seq and analysis 
For Figure 15, RNA from five scraped tracheas was pooled in duplicate 
experiments and submitted to the Vanderbilt Technologies for Advanced 
Genomics core for library preparation and RNA-seq.  For Fig. 15 and Fig. 16, 
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duplicate samples for each of the four genotype/expression conditions (total n=8) 
were submitted to the HudsonAlpha Genomic Services Lab for library preparation 
and RNA-seq.  For both experiments, reads were trimmed to remove adapter 
sequences with Flexbar v2.4 357 and aligned to mm10 using STAR 365 v2.4.2a 
with GENCODE 366 M7 comprehensive gene annotations.  Cufflinks v2.1.1 367 
was used to assemble transcripts and quantify their abundance.  Cufflinks FPKM 
estimates were converted to TPM estimates368.  For differential gene expression 
analysis, reads were assigned to GENCODE M7 comprehensive genes using 
feature Counts 369 (v1.4.6-p5) and tested for differential expression using 
DESeq2 370 v1.8.1 with default parameters.  Genes with an adjusted p-value <0.1 
in the DESeq2 output were considered significantly differentially expressed.  Raw 
sequencing data have been deposited at the NCBI Sequence Read Archive 
under bioproject number PRJNA310161.    
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CHAPTER III 
 
p73 IS REQUIRED FOR MULTICILIOGENESIS AND REGULATES THE 
FOXJ1-ASSOCIATED GENE NETWORK 
Introduction 
The p53 family of proteins, including p53, p63 and p73, are sequence-
specific transcription factors required for cell cycle control, DNA repair, apoptosis 
and cell differentiation15,18,21,371,372.  There are functional and physical interactions 
amongst the family, including coordinate binding and regulation of target genes.  
p63 and p73 have two promoters; isoforms transcribed from P1 contain a 
transactivation domain (TAp63 and TAp73), whereas isoforms transcribed from 
P2 lack the TA domain (∆Np63 and ∆Np73) and have been shown to act in a 
dominant-negative manner to TA isoforms15,21. 
p73 and p63 share 63% and 60% sequence identity, respectively, with the 
p53 DNA binding domain, and the residues that contact DNA are identical.  In 
contrast to the tumor-suppressive role of p53, p63 is essential for maintaining the 
progenitor cell populations required to sustain epithelial development and 
morphogenesis23.  p63-null mice die shortly after birth and exhibit profound 
developmental defects in ectodermal-derived tissues22,23,85.   
Compared to p53 and p63, the physiological role of p73 is poorly 
understood.  Mice lacking p73 exhibit runting, sterility, hippocampal dysgenesis, 
hydrocephalus and chronic infection and inflammation in the lungs, sinus and 
ears16.  To date, no unifying mechanism has been identified to explain these 
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diverse phenotypes.  Through analysis of a p73-deficient mouse model 
developed in our laboratory, we discovered that the affected tissues share in 
common a loss of multiciliated cells (MCCs). 
Motile cilia are located on the apical surface of epithelial cells lining tissues 
that require fluid movement.  Coordinated beating of cilia is essential for 
mucus/infiltrate clearance in the airway, sinus and ears and the prevention of 
infections and inflammation in these tissues373.  In the reproductive tract, 
dysfunction of motile cilia lining the efferent duct and oviduct has been implicated 
in the sterility of both males and females297,298.  In the brain, lack of ependymal 
flow due to defective motile cilia can cause closure of the cerebral aqueduct and 
result in hydrocephalus and hippocampal dysgenesis220,299,302.  In all of these 
tissues, transcription factor Forkhead box J1 (Foxj1) is required for the 
transactivation of genes encoding proteins involved in ciliogenesis.  In Foxj1-
deficient mice, multiple basal bodies are produced, however the basal bodies do 
not dock properly on the apical surface of the cell to initiate the formation of cilia, 
leading to dysfunctional MCCs339.   
We provide evidence that p73 is a direct regulator of Foxj1 and is required 
for proper MCC differentiation1.  In addition, we found that p73 is expressed in 
terminally-differentiated MCCs as well as a subset of basal cells in the tracheal 
epithelium.  p73-/- mice exhibit hyperplasia of epithelial cells followed by loss of 
the airway epithelium in older animals, implying that p73 may also be required for 
airway homeostasis.  Using in situ protein-DNA crosslinking in the tracheal 
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epithelium and chromatin immunoprecipitation with massively parallel DNA 
sequencing (ChIP-seq), we found that p73 binds in close proximity to 105 cilia-
associated genes, some of which have been previously described as regulators 
of MCC development.  We identified three p73 binding sites within 10,000 base 
pairs of the Foxj1 transcriptional start site (TSS) and discovered that p73 
regulates and is required for Foxj1 expression in primary cultures of tracheal 
epithelial cells1. 
Results 
p73-/- Mice Lack MCCs, Have Areas of Focal Epithelial Hyperplasia but 
Overall Loss of Airway Epithelium 
Our p73 knockout mouse model exhibits phenotypes previously reported 
in p73-deficient animals16, including runting (Figure 4A); hippocampal 
dysgenesis; hydrocephalus (Figure 4B); chronic infections and inflammation of 
the lungs, middle ear and sinus (Figure 4B) as well as increased mortality (Figure 
5A) and  sterility (Figure 5B).   Through histological analysis, we noted defects in 
the developing follicles of the p73-/- females (Figure 5C) as well as severe 
degeneration as well as compaction of seminiferous tubules of the p73-/- males 
(Figure 5D).  After histological analysis, we noted an apparent absence of MCCs 
in p73-/- mice and hypothesized that the loss of this cell type could provide a 
unifying mechanism for the well documented, multi-organ defects occurring in 
these animals. 
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Figure 4. Novel p73 Knockout Mouse Recapitulates Earlier Published 
Phenotypes (A) Box and whisker plot representing the weight of mice from E14.5 
through P28.  More than eight mice were weighed from  p73+/+ (red), p73+/- (gray), 
and p73-/- (blue) at the given timepoints. . p-values are annotated as <0.0001 (•••) and 
<0.001 (••). Littermate male p73+/+ and p73-/- mice photographed at P28. (B) 
Micrographs of H&E stained tissues representing reported phenotypes of 
Hydrocephalus, Mucopurulent rhinitis, Mucopurulent otitis, as well as obstruction to 
airways observed in the p73-/- animals. Mouse targeting strategy was designed by 
Mark Magnuson, Jennifer Rosenbluth, and Lucy Tang.  All data represented was 
collected by Clayton Marshall with technical assistance from Deborah Mays. 
   
	 66	
		
Figure 5. p73-/- Mice Have Increased Mortality and are Sterile (A) The 
viability of 12 litters of pups was tracked graphically represented here. (B) 
Eight pairs of each genotype were placed with the opposite gender for 14 days 
to observe if the animals were fertile.  (C) representative micrographs of H&E 
stained ovaries from p73+/+ and p73-/- post-puberty animals.  (D) 
Representative micrographs of H&E stained  p73+/+ and p73-/- testis  of six 
month old males.  The testis of males ranging from two to six months old were 
weighed and are represented in the column graph.   . p-value of  <0.001 is 
represented as (••).  Representative micrographs of seminiferous tubule 
degeneration and compaction observed in p73-/- animals.  All data 
represented was collected by Clayton Marshall. 
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To confirm the absence of MCCs, we performed hematoxylin and eosin (H&E) 
staining and immunofluorescence (IF) detection of p73 and acetylated alpha-
tubulin (*α-tubulin), a well-established marker of cilia374.  In contrast to p73+/+ 
control animals, we observed a lack of cilia in the oviduct, middle ear and sinus 
mucosa, flagella of sperm in the testis, and respiratory tract of p73-/- mice  
(Figure 6A).  We also noted a lack of MCCs in the ependymal cells (data not 
shown).  It was recently reported that p73 is strongly expressed in murine ciliated 
ependymal cells and is required for their survival107.  p73 protein expression 
appeared nuclear by IF and was detected in the epithelium of *α-tubulin-positive 
tissues in p73+/+ animals (Figure 6A).  To determine if ciliated epithelium failed 
to develop in utero or was lost over time after birth, as well as to determine if 
other members of the p53 family have roles in MCC development, we performed 
IF for *α-tubulin on the respiratory tracts of E18.5 wild type mice and animals 
deficient in p5332, p6333, or p73.  We found p73 knockout animals lacked cilia in 
bronchioles in utero, p63-/- animals had increased cilia as previously reported250 
and p53-/- animals were similar to wild type (Figure 6B).   
The p73 mouse model characterized herein was generated by flanking 
exons 7 through 9 of p73 with tandemly-oriented loxP sites by gene targeting in 
mouse ES cells (Figure 7A and Experimental Procedures).  Mice containing the 
p73floxE7-9 allele were bred with CMV-Cre mice to globally impair p73 in all tissues 
(p73-/-).  Sanger sequencing of p73 cDNA verified that p73-/- animals express an 
mRNA variant that encodes the amino-terminal portion of the protein up to Q243 
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Figure 6. Global Ablation of p73 Eliminates MCCs (A) Representative 
H&E and immunofluorescence (IF) micrographs of the indicated tissues from 
p73+/+ and -/- mice. Arrowheads mark cilia and flagella (testis). IF was 
performed using antibodies recognizing the cilia marker *α-tubulin (green) 
and p73 (red). (B) Representative micrographs of IF staining of *α-tubulin in 
embryonic day 18.5 tracheas and lungs from p53-/-, p63-/- and p73-/- 
animals. (scale bars = 25 µm). All data represented was collected by Clayton 
Marshall. 
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(in exon 6), which is then spliced to the codon for the first amino acid in exon 10, 
V358 (Figure 7B).  This truncated version of p73, which lacks part of the DNA 
binding domain, nuclear localization signal, and oligomerization domain6, is 
functionally inactive as a transcription factor.  qRT-PCR from p73-/- animals 
confirmed loss of full-length p73 mRNA (Figure 7C).   Western blot analysis of 
lung tissue also showed loss of the full-length p73 protein and appearance of a 
faster-migrating immunoreactive band in p73+/- and p73-/- animals, with a 
molecular weight consistent with expression of a truncated p73 protein (Figure 
7D).  By IF staining, the truncated p73 protein is occasionally visible in the 
cytoplasm of p73-/- cells (Figure 6A).   
To further validate the role of p73 in proper MCC differentiation, murine 
tracheal epithelial cells (MTECs) were isolated from p73+/+ and p73-/- mice as 
previously described and grown as air liquid interface (ALI) or 2-D submerged 
cultures355,356.  Under either culture condition, MCCs were not evident until 
differentiation was induced by transfer of confluent cultures to differentiation 
media355,375.  After transfer to differentiation media in ALI or 2-D culture, *α-
tubulin-positive MCCs were observed in p73+/+ MTECs but not in p73-/- cells, 
recapitulating the phenotype we observed in vivo (Figure 6 and 7E).  To evaluate 
potential confounding effects of the truncated, cytoplasmic protein generated in 
our p73 knockout model, we expressed two shRNAs targeting exon 6 and the 3’-
UTR of p73 in the p73+/+ and p73-/- MTECs.  In p73+/+ cells, we observed an 
acute loss of p73 expression and a concomitant loss of *α-tubulin- 
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Figure 7. Generation of the p73floxE7-9 Mice  (A) Sanger sequencing of a PCR 
product from lung cDNA indicates in-frame splicing of exons 6 and 7 (p73+/+) and 
exons 6 and 10 (p73-/-). (B) qRT-PCR of lung cDNA was performed using primers 
within exon 5, across the exon 6/7 boundary, and within exon 10 of p73. Data are 
represented as normalized ratios of p73-/- to p73+/+ mRNA expression. (C) 
Western analysis of protein harvested from lung tissue of the indicated genotyped 
animals shows absence of full-length p73 protein in the p73-/- animals and a faster 
migrating immuno-reactive band in the p73+/- and -/- samples, with a molecular 
weight consistent with expression of a p73 protein lacking exons 7-9 (* = non-
specific band). (D) Micrographs of MTECs isolated from tracheas of p73+/+ or p73-
/- animals, infected with non-silencing (NS) or two different p73 short hairpin RNA 
silencing constructs (shRNA 1 & 2), and grown in differentiation media. 
Representative IF staining of p73 (red) and *α-tubulin (green) is shown for each 
condition. Arrows indicate cilia and flagella within p73+/+ animals.  All data 
represented was collected by Clayton Marshall with technical assistance from 
Deborah Mays. 
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positive MCCs (Figure 7E).  In p73-/- MTECs, shRNA expression resulted in loss 
of the cytoplasmic, truncated p73 visible in control cells (Figure 7E, arrowheads); 
after knockdown, these cells were still unable to differentiate into MCCs (Figure 
7E).  These data confirm that both p73 mRNA knockdown and p73-/- exon 7-9 
deletion led to an absence of MCCs, ruling out confounding or dominant-negative 
effects of the truncated protein observed in p73-/- cells. 
To evaluate the long-term consequences of MCC loss in p73-/- mice, we 
necropsied 10 mice of each genotype at 18 months of age.  In contrast to p73+/+ 
controls, all p73-/- mice evaluated had significant loss of epithelium in a majority 
of bronchioles with areas of focal hyperplasia (Figure 8A) that were positive for 
expression of cytokeratins (Figure 8B).  In the areas of epithelial loss, there was 
hypertrophy and hyperplasia of underlying alpha smooth-muscle actin (α-SMA)-
positive cells (Figure 8B).  The lack of MCCs led to retained debris, mucus and 
inflammatory cells in the bronchioles, which resulted in crystalline pneumonia in 
many animals (Figure 9A).  This loss of bronchiole epithelium was exhibited as 
early as six months of age (data not shown) and its severity increased in the 
older animals.  We also observed chronic mucopurulent otitis and rhinitis in our 
p73-/- animals of all ages (Figure 9B), consistent with previous reports16.   
We did not observe tumor formation in p73-/- animals.  Both our model 
and the mice previously generated by the McKeon group16 harbor functional 
inactivation of both TA and ∆N isoforms of p73, and neither model exhibits an 
increased susceptibility to lung tumors.  TAp73 has been 
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Figure 8. p73-/- Mice Exhibit Severe Airway Phenotypes Including 
Hyperplasia and Epithelial Loss (A) Representative H&E images of the 
terminal airways in 18 month old p73+/+ and p73-/- mice. The p73-/- mice 
exhibit areas of epithelial loss (arrow) and small nodules of hyperplastic 
epithelium (+). (B) Immunohistochemistry (IHC) staining of pan-cytokeratin and 
α-SMA of above mice. Arrows in panel B indicate areas of epithelial loss as 
well as hypertrophy and hyperplasia of the smooth muscle (scale bar= 50 µm). 
 All data represented was collected by Kelli Boyd. 
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Figure 9. p73-/- Mice Show Evidence of Infection and Inflammation in 
the Lung, Sinus and Ears (A) Representative images of alcian blue (top 
panel) and H&E (bottom panel)-stained lungs from p73+/+ and p73-/- mice. 
Mucin-producing cells and retained mucus are stained blue. (B) 
Representative H&E images of sinus and ears of p73+/+ and p73-/- mice. 
The external ear canal (EC), middle ear (ME), tympanic membrane (TM) 
and malleus (M) are labeled. Arrows indicate areas of mucus and 
inflammation in the upper and lower panel, respectively. All data 
represented was collected by Kelli Boyd and Clayton Marshall. 
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 demonstrated to possess tumor suppressive activity in vivo, as knockout of this 
isoform without removal of ΔNp73 in mice led to spontaneous lung 
adenocarcinoma17.  We hypothesize that the loss of all isoforms of p73 results in 
a reduction or an absence of lung tumor progenitor cells.   
The Airways of p73-/- Mice Have Reduced Numbers of Basal cells in 
Addition to MCC-Deficient Phenotype  
To determine the impact of MCC loss on the distribution of other cell types 
in the murine airway, we performed IF with antibodies to well-established cell-
type specific markers including: Scgb1a1 (club), Foxj1 (MCC), Pgp9.5 
(neuroendocrine), Alcian blue (mucin) and p63 (basal) (Figure 10; data are 
presented as percentage of total epithelial cells with representative micrographs 
in Figure 11).  In p73-/- mice, we observed a 90% loss of Foxj1-positive MCCs in 
the trachea and bronchiole (p<0.0001), a 35% reduction of basal cells in the 
trachea (p<0.0001), and a significant increase in mucin-producing, club, and 
neuroendocrine cells throughout the airway (Figure 10).  In p73+/- mice, MCCs 
were reduced by 23% and 44% in the trachea and bronchiole, respectively. 
The Airways of p63-/- Mice Have Reduced Numbers of Club and Basal Cells 
 p63 is commonly used as an airway basal cell marker34,241,251 and is 
implicated in regulation of the murine tracheal epithelium250 and human bronchial 
cell differentiation253.  In p63-/- mice, we observed an increase in MCCs, 
	 75	
	
  
Figure 10. Loss of p73 and p63 in the Respiratory Epithelium Leads 
to Significant Changes in Cellular Composition. Respiratory 
epithelium from murine tracheas and bronchioles with the indicated 
genotypes were analyzed for cell type as percent of total DAPI nuclear 
marker. Due to the perinatal lethality of p63-/- mice, E18.5 mice were 
assessed for this genotype. Both E18.5 and post-pubertal mice were 
assessed for p73 genotypes. Manual quantification was performed on 
micrographs from at least eight animals with four fields of view per 
animal. Representative images can be found in Figure S3. p-values are 
annotated in the table under the bar graphs in panels A and B as <0.0001 
(•••), <0.001 (••), and <0.01 (•).All data represented was collected by 
Clayton Marshall. 
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neuroendocrine and mucin cells and a reduction in basal and club cells (Figure 
10).  These data suggest that the lack of p63-positive basal cells results in a shift 
in cell fate specification away from the club cell lineage.   
p73 is Expressed in Basal Cells of the Airway Epithelium and Co-
Expressed with Foxj1 in MCCs  
To further assess cell types in which p73 is expressed, we performed dual 
IF for p73 and Foxj1, a protein marker of MCCs that is required for motile 
ciliogenesis.  In both bronchioles and trachea, all Foxj1-positive cells express 
p73 (Figure 12A, table).  In the trachea, however, not all p73-positive cells 
express Foxj1.  We observed p73 single positivity in ~13% of total p73-positive 
cells, and these cells appeared basally located (Figure 12B, table).  Thus, p73 is 
not solely expressed in terminally differentiated MCCs in the trachea.   
Co-staining of p73 and p63 identified three populations of cells: p73 
single-positive, p63 single-positive and p73/p63 dual-positive cells (Figure 12B).  
We found that p73 is expressed in almost 50% of the tracheal epithelial cells and 
is co-expressed with p63 in a fraction of basal cells (Figure 12B).  Of the p63-
positive basal cells, 50% were p63 single-positive and 50% were dual-positive for  
Figure 11. Representative Images from the Trachea and Bronchioles Used 
for the Quantification of Respiratory Epithelium Cell Types Shown in 
Figure 10. IF detection of the indicated proteins in murine tracheal and 
bronchiolar tissue from mice of the indicated genotype. Foxj1 (green) was used 
as a marker of the ciliated cells. Scgb1a1 (red) was used as a marker of club 
cells. Alcian blue staining was used to detect mucin-producing goblet cells. 
Pgp9.5 (yellow) was used as a marker of neuroendocrine cells. p63 (red) was 
used as a marker of the basal cells within the murine trachea (scale bars = 25 
µm). All data represented was collected by Clayton Marshall. 
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Figure 12. p73 is Expressed in a Subset of Basal Cells in the Murine 
Trachea as well as in MCCs Representative IF staining of murine 
tracheas and bronchioles. (A) p73 (red) is 100% co-localized with Foxj 
(green) in MCCs in the bronchioles (upper panel). p73 (red) co-localizes 
with Foxj1 (green) in a subset of cells in the trachea (lower panel). (B) IF 
staining of p73 (red) and p63 (green) shows co-localization of p63 and p73 
in a subset of basal tracheal epithelial cells (scale bars = 25 µm). Tables 
provide the percentage of cells that have single or dual expression of p73, 
p63 or Foxj1. Values represent the average of 32 fields of view that were 
quantified (four views from eight animals). All data represented was 
collected by Clayton Marshall. 
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p63 and p73 (Figure 12B).  Similar percentages were identified using the 
alternative basal cell markers Krt5 and Krt14 (Figure 13). 
To assess the expression pattern of p73 in human airways, we conducted 
IF staining of normal lung tissue from 10 individuals.  The human lung epithelium 
is highly ciliated, with a greater number of cells expressing p73 compared to mice 
(Figure 12 and 14).  As in mice, expression of p73 is localized proximally to *α-
tubulin (Figure 14A), and Foxj1 co-localizes with p73 in the nucleus of all ciliated 
cells (Figure 14B).  Consistent with the murine lung, we found dual expression of 
p73 and p63 in a subset of basal cells (Figure 14C), supporting a model whereby 
p73 is an early marker for the MCC lineage and regulates the MCC differentiation 
process through its activity as a sequence-specific transcriptional 
regulator15,18,21,35,68.   
In situ p73 and p63 ChIP-seq in Murine Tracheal Epithelial Cells  
 To identify genomic loci to which p73 and p63 are bound in airway 
epithelium in vivo, we performed in situ protein-DNA crosslinking in the murine 
tracheal epithelium at the time of euthanasia.  The tracheal epithelial cells from 
50 p73+/+ mice were cross-linked in situ, harvested, and processed in duplicate 
for p73, p63, and RNA polymerase II (Pol II) ChIP-seq as described in 
Experimental Procedures.   
Twenty to fifty million single-end 50 bp reads were generated for each 
ChIP-seq library.  The resulting sequencing reads were aligned to the mouse 
genome and genomic binding sites enriched in each condition were identified 
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Figure 13. p73 is Expressed in a Subset of Basal Cells Within the 
Murine Airway Representative IF micrographs for the indicated proteins 
on sections of lung tissue from murine trachea . (A) KRT5 and KRT14 
(green) and p73 (red) staining is consistent with a subset of murine 
tracheal basal cells express p73.   All data represented was collected by 
Clayton Marshall. 
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Figure 14. p73 is Expressed in Ciliated and Basal Cells Within the Human Airway 
Representative IF micrographs for the indicated proteins on sections of lung tissue from 
ten individual human patients . (A) *α-tubulin (green) and p73 (red) staining is consistent 
with a much higher percentage of MCC in human bronchiolar epithelium as compared to 
murine. (B) Foxj1 (green) and p73 (red) staining showing basal cells with single p73 
positivity as well as luminal MCCs with co-expression of p73 and Foxj1. (C) p63 (green) 
and p73 (red) IF shows basal localization of p63 while p73 protein expression patterns 
are similar to that observed in the murine tracheal epithelium - both basal and ciliated 
(scale bar= 50 µm).  All data represented was collected by Clayton Marshall. 
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 using input DNA as a control.  When comparing read coverage at identified 
binding sites, we found the replicates to be similar (Pearson correlation of 0.85, 
0.92 and 0.95 for p73, p63 and Pol II, respectively) (Figure 15A); thus, each 
condition was pooled for further analyses.  
In total, we identified 1,767 (p73), 3,861 (p63) and 53,684 (Pol II) genomic 
binding sites (Figure 15C).  The median distance from p73 and p63 binding sites 
to the nearest transcriptional start site (TSS) was 9,531 and 12,810 bp, 
respectively (Figure 15C).  We observed a significant enrichment of p73, p63 and 
Pol II binding in transcriptionally active areas of the genome such as promoters, 
5’ UTRs, and exons, with a lack of enrichment in intragenic regions (Figure 15B). 
Based on our finding that p73 was bound to transcriptionally active areas 
of the genome, we tested the hypothesis that genes bound proximally by p73 
exhibit higher RNA expression.  At the time of tracheal ChIP-seq, we performed 
parallel RNA-seq from tracheal epithelium to determine expression levels of 
genes within the tissue.  ChIP-seq and RNA-seq data were combined to generate 
a cumulative distribution function (CDF) of RNA expression for genes with 
observed p73 binding within 25,000 bp of a TSS versus those without.  Analysis 
of the CDF indicates that genes with p73 binding within 25,000 bp of their TSS 
are more likely to be expressed and have higher RNA expression than genes 
without (Figure 15D). 
Motif analysis showed enrichment of the p53 family binding motif30,31,376-380 
within p73 and p63 genomic binding sites (1764 of 1767 and 3846 of 3861, 
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respectively) (Figure 15E).  Our ChIP-seq analysis identified well-validated p73 
and p63 target genes such as Mdm2, Cdkn1a, Bbc3, and Jag1; and, example 
genomic binding profiles of Mdm2 and Cdkn1a 381-383 are presented in Figure 
S5F384,385.   
p73 Binds and Regulates Genes Required for the Development and 
Function of MCCs 
In order to identify a mechanism for the loss of MCCs in p73-/- mice, we 
analyzed the nearest protein-coding genes whose TSS fell within 25,000 bp of 
p73 genomic binding sites.  We identified 1,011 such genes nearby 1,096 binding 
sites.  Many of these putative target genes have documented roles in MCC 
formation and maintenance.  To formally test for overrepresentation of genes 
involved in multiociliogenesis, we obtained a list of cilia-associated genes 
identified through previously published, single-cell RNA-seq364.   Overall, we 
observed highly significant overrepresentation of the cilia-associated gene set 
within our p73-proximal protein-coding genes (p=4.53E-06).  The 105 
overlapping genes are listed in Figure S6. 
To determine if the putative target genes could be transcriptionally 
regulated in a p73-dependent manner, we infected p73+/+ and p73-/- MTEC 
cultures with a lentivirus containing a TAp73β expression construct or an empty 
vector control. We grew the cells as ALI cultures, performed RNA-seq, and 
conducted differential gene expression analyses comparing p73 overexpression 
to vector control for each genotype (Table 16).  Of the 21,867 protein-coding 
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genes queried, more than 3,300 were significantly differentially expressed after 
ectopic expression of p73 in both p73+/+ and -/- MTECs.  (Figure 16A).  
Importantly, genes with p73 binding sites within 25 kb of their TSS were 
specifically enriched among differentially expressed genes (Figure 16A).  Among 
the 105 genes overlapping with the cilia-associated gene set, 49 had significant, 
p73-dependent changes in gene expression in p73+/+ or p73-/- MTECs (Figure 
Figure 15.  Analysis of DNA-Binding Profiles after in situ Protein-DNA 
Crosslinking and ChIP-seq (p73, p63 and Pol II) of Murine Tracheal Cells 
(A) Heatmap of hierarchically clustered Pearson correlations between ChIP-seq 
samples. (B) Analysis of the genomic features of the p73, p63 and Pol II binding 
sites. The first column under each protein section indicates the number of peaks 
observed within each respective genomic feature. The second column indicates 
the log ratio of binding enrichment for the peaks identified over the expected 
overlap based on the size of the given genomic feature. The final column lists 
the p-values for the observed enrichment of each feature type. (C) Summary of 
the number of binding sites and median distance to transcriptional start sites 
(TSS) for the Pol II, p73, and p63 ChIP-seq datasets. (D) CDF plot comparing 
the RNA expression levels of genes bound by p73 within 25,000 kb of their TSS 
versus genes not bound. Significance testing was performed using the 
Kolmogorov-Smirnov test. (E) Binding motifs identified in p73 and p63 ChIP-seq 
peaks. (F) Table of binding profiles of known target genes Mdm2 and Cdkn1a, 
including the q-value significance of the binding sites observed at each of the 
genes, and the bp distance from the middle of each binding site to the TSS, 
along with notation for whether a corresponding p63 binding site was found at 
the same location. Below the table are Integrative Genomics Viewer 
screenshots of Mdm2 and Cdkn1a in which the four tracks show ChIP-seq data 
normalized to 1x depth of coverage and presented with identical scales. The 
bottom three tracks represent DNA reads that were obtained following ChIP with 
the antibodies listed to the left, and the top track is the input sample for 
comparison. At the bottom of each panel is an annotated exon/intron gene 
structure displayed on the same scale as the ChIP-seq tracks with a gray arrow 
at the bottom annotating the gene orientation. Data was generated by Clayton 
Marshall through collaboration with Bryan Venters.  Clayton Marshall was 
assisted in bioinformatic analysis by Scott  Beeler and Timothy Shaver. 	
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17, highlighted in gray).  Of immediate interest were 14 genes that have been 
reported to have roles in MCC differentiation and homeostasis386-388 (Figure 16B), 
including Foxj1, Traf3ip1, and Spata18 (Figure 16C).  We found that greater than 
25% of genes in the cilia-associated gene set (397/1398) were differentially 
expressed after ectopic p73 expression, not just those with p73 binding sites 
nearby (Figure 16A).  These data support a model in which p73 acts as a 
regulator of multiciliogenesis through both direct and indirect regulation of key 
genes. 
The protein-coding gene with the most significant differential expression 
after rescue of p73-/- MTECs by ectopic p73 expression was a key regulator of 
ciliary biogenesis, Foxj1.  We identified three dual p73/p63 genomic binding sites 
within 10,000 bp of the Foxj1 TSS (Figure 16B and C).  Traf3ip1 (Figure 16B and 
C) had the most significant q-value from the p73 ChIP-seq and has been 
previously shown to bind basal bodies and regulate the acetylation of 
microtubules389.   Also present in our p73 and p63 ChIPseq datasets are Jag1, a 
known p73 and p63 target gene390 and a regulator of the Notch pathway 
implicated in ciliogenesis238.  The Rfx family member, Rfx3 was also in the p73 
dataset.  The Rfx family of transcription factors is implicated in regulation of 
ciliary biogenesis308. We additionally provide evidence that Spata18, a target 
gene of both p53 and p63391, is regulated by p73 (Figure 16B and C).  
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To determine whether the p73-dependent increase in Foxj1 mRNA 
required differentiation cues from the culture medium or if p73 expression alone 
was sufficient to modulate Foxj1, we analyzed expression of p73 and Foxj1 in 
parallel cultures of submerged p73+/+ and p73-/- MTECs under non-
differentiating culture conditions, with and without ectopic expression of p73.  
Infection of p73+/+ MTEC cultures with a control lentiviral vector resulted in very 
few p73-positive cells and no Foxj1-positive cells.  Under the same conditions, no 
p73- or Foxj1-postitive cells were observed in p73-/- MTECs cultures.  However,  
Figure 16. p73 Binds and Regulates Target Genes Found in Cilia-Associated Gene 
Set (A) Table showing differentially expressed genes in indicated MTECs after ectopic p73 
expression (results shown are relative to control). Cells were infected with a lentivirus 
containing a TAp73β overexpression construct or an empty vector control. Cultures were 
maintained for five days in basal growth media and one day in differentiation media, 
followed by RNA harvest and sequencing. Differential gene expression analysis between 
duplicate p73 overexpression and control samples was performed for each genotype. The 
number of differentially expressed genes (adjusted p-value <0.1) was quantified for four 
different categories: all protein-coding genes (All Genes), genes with p73 binding sites 
within 25 kb of their transcriptional start sites (TSS) (p73 Proximal Genes), a Cilia-
Associated Gene Set, and the overlap of the previous two categories (p73 Proximal Cilia-
Associated) For the three latter categories, the p-value for category-specific enrichment 
versus all protein-coding genes was calculated using the hypergeometric test. (B) Table 
indicating cilia-associated genes bound and regulated by p73. For each binding site, the q-
value significance and distance to the respective TSS are indicated along with notation for 
whether a corresponding p63 binding site was found at the same location. For each gene, 
the log2 fold change and adjusted p-value from the differential gene expression analysis 
performed in A are presented. p73 (**) is included as a reference for expression change and 
genes are ordered based upon increasing q-value. (C) Integrative Genomics Viewer 
screenshots for select genes from panel B in which the four tracks show ChIP-seq data 
normalized to 1x depth of coverage and presented with identical scales. The bottom three 
tracks represent DNA reads that were obtained after ChIP with the antibodies listed to the 
left, and the top track is the input sample for comparison. At the bottom of each panel is an 
annotated exon/intron gene structure displayed on the same scale as the ChIP-seq tracks, 
and the arrow in the bottom left annotates the gene orientation.  Data was generated by 
Clayton Marshall through collaboration with Bryan Venters.  Clayton Marshall was assisted 
in bioinformatic analysis by Scott  Beeler and Timothy Shaver. 
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after ectopic TAp73β expression, we observed increased expression of Foxj1 in 
both p73+/+ and p73-/- MTEC cells (Figure 18A).  These data indicate that p73 is 
sufficient to modulate Foxj1 expression in the absence of differentiation media 
and demonstrate the ability of ectopic p73 expression to rescue Foxj1 expression 
in p73-/- MTECs.    	In parallel experiments, MTEC cultures were transferred to differentiation 
media after lentiviral infection.  We observed an increase in p73 and Foxj1 
expression in p73+/+ MTECs under both expression conditions, consistent with a 
differentiation-induced elevation of p73 and Foxj1 expression.  However, Foxj1 
expression was not detectable in the control p73-/- MTEC cultures and only 
became apparent after ectopic expression of p73 (Figure 18B).  Twenty-four 
fields of view of IF staining from quadruplicate experiments of cells cultured in 
differentiation media were quantified and showed tight concordance between p73 
and Foxj1 expression (p< 0.001) (Figure 18B).   
In summary, p73 binds to three sites within 10,000 bp of the Foxj1 TSS.  
Further, ectopic p73 expression is sufficient to upregulate Foxj1 expression in  
Figure 17.  Additional p73 Binding to Novel Target Genes in Cilia-Associated 
Gene Set At top, a Venn diagram illustrates the overlap of genes featuring a p73 
binding site within 25 kb of their transcriptional start site (930 total) with the cilia-
associated gene set (1398 total). The 105 overlapping genes are detailed at bottom. 
For each gene, the q-value significance and distance to the respective TSS for the 
associated binding sites are indicated along with notation for whether a 
corresponding p63 binding site was found at the same location. Genes are ranked by 
decreasing q-value and are highlighted in gray if they were significantly differentially 
expressed after exogenous overexpression of p73 in either p73+/+ or p73-/- MTEC 
cultures.   Data was generated by Clayton Marshall through collaboration with Bryan 
Venters.  Clayton Marshall was assisted in bioinformatic analysis by Scott  Beeler 
and Timothy Shaver. 	
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MTEC cultures in the absence of differentiation signaling and rescues Foxj1 
expression in a p73-/- background.  Collectively, the data provide evidence that 
p73-dependent regulation of a cilia-associated gene network plays a causative 
Role in licensing cells to the MCC fate.  	
Discussion 
Herein we report that p73 is required for the formation of MCCs in mice 
through binding and regulation of a broad array of gene targets.  Of importance is 
our finding that p73 directly modulates Foxj1 and a network of cilia-associated 
genes required for the development of MCCs in the airway, choroid plexus, 
ependyma, oviducts and testis of mice334,336,339,340,392-395.  We propose that like its 
family member p63, p73 is required for tissue-specific cell differentiation through 
its role as a sequence-specific transcription factor.   Given our finding that p73 
regulates a cilia-associated gene signaling network required for proper MCC 
differentiation, it will be of interest to determine the interplay of p73 target genes 
with other pathways involved in MCC lineage formation, including those 
controlled by E2f4396, Myb346,347, Mcidas345, Ccno397, the Rfx family308 and the 
Figure 18. p73 Regulates the Expression of Foxj1 (A) MTECs were infected with a 
lentivirus containing a TAp73β overexpression construct (Ectopic p73) or an empty 
vector control (Control) and grown in basal growth media for three days, after which 
immunofluorescence (IF) was performed for the indicated proteins. (B) Parallel cultures 
were transferred to differentiation media for three days after three days of growth in 
basal media and stained identically. For both panels A and B, DAPI counterstaining 
(blue) was performed to determine the percentage of cells expressing the indicated 
proteins. The bottom graph presents quantification of p73- and Foxj1-positive cells 
averaged from quadruplicate experiments with six fields of view per condition (•• 
represents p-value <0.001, ••• represents p-value <0.0001) with error bars representing 
standard deviation.  All data represented was collected by Clayton Marshall with 
technical assistance from Deborah Mays. 
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Notch family238. 
The observed co-expression of p73 with p63 in a subset of basal cells 
lining the tracheal epithelium raises the possibility that similar to p63, p73 is 
involved in progenitor cell fate determination and is required for MCC 
specification and differentiation.  In the respiratory epithelium, p63 expression is 
restricted to basal and progenitor cells235,253,398.  Unlike in skin, where p63 is 
necessary for the development and maintenance of a stratified epithelium22,23, a 
subset of airway luminal cells forms in the absence of p63250,253.  Because p63-
null animals die at birth, the long-term functionality of their airway epithelium 
cannot be determined; future studies are needed to determine how targeted 
ablation of p63 and p73 in adult mouse tracheas affects homeostasis and repair 
of the airway after damage.  Greater understanding of the functional interaction 
between p53 family members in the airway epithelium has implications for both 
regenerative medicine and prevalent diseases such as COPD and asthma. 
p73 and p63 heteroligomerize when co-expressed; as such, it is difficult to 
study the transcriptional activity of p73 in basal cells of the airway without 
considering the contribution of p63399.  ∆Np63 has the ability to bind TAp73 and 
act as a transcriptional repressor of p7391,400.  To parse the individual functions of 
these proteins, future transcriptional profiling experiments are needed in which 
cells are separated into p73 and p63 single- and dual-positive populations.  The 
engineering of mouse models to enable p73- and p63-specific lineage tracing 
during development and in response to damage would also be of significant 
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value in defining the unique and overlapping roles of these developmental 
regulators. 
From analysis of our ChIP-seq data, we observed that p73 and p63 co-
occupy 804 genomic loci.  We hypothesize that p63 represses the expression of 
many of these genes within dual-positive, MCC-specified basal cells until a signal 
promotes differentiation.  This might occur by several mechanisms: p73 protein 
levels may increase, p73 binding and distribution on the chromatin may shift, 
changes in the stoichiometry of TAp73 versus ∆N expression may occur relative 
to p63 levels, or p63 levels or chromatin binding may be reduced.  Future studies 
investigating the mechanism by which the balance of p63 and p73 signaling is 
regulated in the airway epithelium in response to developmental cues and cellular 
stress will be of interest in both development and disease. 
After ectopic expression of p73 in MTEC cultures, we observed a 
significant increase in the expression of many cytokeratins, including Krt5 and 
Krt14; however, our ChIP-seq data did not indicate a TSS-proximal p73 binding 
profile for these genes in adult mouse trachea.  Further studies are needed to 
determine the direct or indirect mechanisms by which p73 and p63 regulate the 
expression of genes required for basal cell maintenance. 
There is a significant reduction in the proportion of basal cells in the 
tracheal epithelium of p73-/- mice.  This reduction implies that p73 is required for 
the maintenance of a subset of basal cells, or that increased differentiation of 
basal cells is required to compensate for a lack of the MCCs due to inflammatory 
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stress in the p73-/- mice.  We did observe an eventual loss of epithelial cells in 
older p73-/- mice, and we hypothesize that the progenitor cell population is 
eventually depleted through constant damage, inflammation and infections from 
impaired clearance of foreign particles and toxins.  Immunohistochemistry (IHC) 
staining of Ki67, a marker of proliferation, we did observe increased positive 
nuclei in murine trachea and bronchioles (Figure 19A).   Further quantification of 
30 fields of view from 1 week old pups to 4 month old animals indicated 
significant increases in the percentage of Ki67 positive cells within the p73-/- 
trachea and bronchioles (Figure 19B).   In the timepoints investigated (1 week-4 
months) to date there was no significant difference in the frequency of epithelial 
cells that exhibit apoptosis through IHC of cleaved Caspase 3 (Figure 19C).  
Further timepoints investigating apoptosis within the p73-/- animals are needed to 
better determine at what point the epithelium is being lost, and if that loss is due 
to apoptosis.  
As early as seven days postnatally, we observed an increased proportion 
of mucin-producing cells in p73-/- mice, perhaps indicating that their airways 
were already challenged due to a lack of MCCs.  The McKeon group reported the 
presence of p63-positive cells in the bronchiolar epithelium of mice that had been 
challenged with H1N1 infection 256, and demonstrated that these distal stem cells 
are required for alveolar regeneration within damaged lungs255,257.  In support of 
this model, we found p63-expressing cells in the bronchiolar epithelium of our 
p73-/- with increased concentration in areas of increased inflammation and  
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Figure 19. p73-/- Mice Exhibit Increased Proliferation of the Bronchiole Epithelium. 
(A) Representative micrographs of IHC staining of Ki67, a marker of proliferation, within the 
trachea and bronchioles of p73+/+ and p73-/- bronchioles. (B) Quantification of 4 fields of 
view from 8 animals ranging in age from 7 days postnatal to 4 months old. Data for the 
tracheal and bronchiole quantification are represented as percentage epithelial cells positive 
to the total number of contiguous epithelial cells within the field of view.  (C) Micrographs of 
IHC staining of cleaved Caspase 3, a marker of apoptosis.  Arrowheads mark nuclei 
counted as positive for each IHC stain. All data represented was collected by Clayton 
Marshall. 
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mucus retention of adult murine bronchioles (Figure 20A).  Analysis of the 
developing lungs additionally supported p63 presence in the airways as a 
reaction to stress.  We did not observe p63 positive cells in the bronchioles of 
embryonic p73-/- animals (Figure 20B).  The first p63 positive cells observed 
were seen as early as 7 days postnatal life (Figure 20B).  We did not observe 
p63 positive cells within the lungs of p73+/+ animals investigated.  Additionally, 
Foxj1 has been previously reported to regulate T cell activation through 
modulation of the NF-κB pathway, with Foxj1 deficiency leading to systemic 
inflammation and autoimmunity defects401.  Given our finding that p73 is a direct 
regulator of Foxj1, future studies are needed to evaluate the mechanistic 
importance of Foxj1 deficiency in the inflammatory defects observed in the p73-/- 
setting. 
Numerous human diseases and conditions have been linked to 
dysfunctional ciliogenesis, including hydrocephalus; hippocampal dysgenesis; 
primary ciliary dyskinesia; Bardet-Biedl syndrome; asthma; anosmia; COPD and 
sterility387,402.  Pointing to a potential link between p53 family members and 
inflammatory stress response in the airway, Li and colleagues observed 
increased levels of p73 and p63 in the hyperplastic regions of patients with nasal 
polyps403, as well as increased cilia density and length404.  Given the findings of 
our study, it would be of interest to investigate the activity of p73 within patient 
samples or mouse models of cilia-related diseases.  With the increased 
availability and depth of GWAS and SNP data, it may also be possible to 
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Figure 20. p63 Positive Cells Observed Within the Bronchioles of p73-/- Animals. (A) 
Micrographs of p63 (red) IF within 6 month old bronchioles of p73+/+ and p73-/- animals.  
(B) IF staining of p63 (red) within developing bronchioles of mice ranging from Embryonic 
day 16 through postnatal day 14.   All data represented was collected by Clayton Marshall.  
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 associate polymorphic variants in the p73 gene with altered expression or 
activity and disease susceptibility.  
Conclusions 
In summary, we discovered that p73 deficiency leads to an organism-wide 
absence of multiciliated cells, providing a unifying mechanism to explain the 
multiple-organ defects observed in p73-/- mice1.  Through in situ ChIP-seq of the 
murine trachea, we identified p73 genomic binding sites in proximity to genes that 
regulate the spectrum of events required for MCC differentiation, from cell cycle 
arrest (Cdkn1a405) and amplification of centrioles (Myb346) to apical docking of 
centrioles with components that make up the axoneme [Foxj1339, Traf3ip1389].  By 
combining our ChIP-seq data with RNA-seq of primary murine tracheal epithelial 
cultures, we obtained evidence for p73-dependent, direct and indirect 
transcriptional regulation of a broad network of cilia-associated genes.  We 
propose a model found in (Figure 21) in which p73 is implicated not only in the 
differentiation of MCCs, but also in MCC homeostasis and thus airway-protective 
function.  We propose that p73 acts as a critical regulator of multiciliogenesis in 
its capacity as a sequence-specific transcription factor, through genomic binding 
and regulation of genes that are required along the continuum of MCC 
development and maintenance. 	
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Figure 21. Graphical Representation of the Role of p73 Within the Pulmonary 
Epithelium On the Left, p73+/+ and p73-/- tracheal epithelium is represented with 
Multiciliated (blue), Basal (green), Mucin (yellow), Club (gray), and Neuroendocrine 
(purple) cells.  Those cells that express nuclear p73 are annotated with nuclei colored 
red.   The p73 transcription factor genomically binds to components with roles 
throughout MCC development (Cdkn1a, Myb, FoxJ1, and Traf3ip1).   	
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CHAPTER IV 
 
MECHANISMS OF p73 REGULATION 
 
Introduction 
Several cellular responses to stress and developmental cues are 
dependent on the transcription factors: p53, p63 and p7312.  This family of 
transcription factors regulate cellular functions including metabolism, apoptosis, 
cell cycle, angiogenesis, differentiation, migration, and motility406.  mRNA variants 
of p73 are generated by alternate splicing and the use of separate, alternate 
promoters.  The different protein isoforms are capable of independent and 
distinct functions depending on the presence or absence of specific domains21,26.  
p73 can be transcribed from two separate promoters.  The first promoter for p73 
is located upstream of the first exon, and the other promoter is located in the third 
intron.   Transcription from the promoter in the third intron creates a truncated 
form of p73 known as ∆Np73 that lacks the TA domain15,38.   ∆Np73 can inhibit 
the activities of full-length p53, p63, and p73 by competition for the same DNA 
binding sites on downstream promoters47.  TAp73 can activate apoptosis through 
transcriptional regulation of p21, BAX, PUMA, NOXA, PIG3, and PARP, all of 
which are common targets shared with p5327. 
From whole genome chromatin precipitation analyses, p53, p63, and p73 
have a significant overlap in transcriptional targets349,378,407,408.  However, 
differential regulation of non-overlapping targets by p53, p63, and p73 is likely 
dependent upon differing DNA binding affinities for select sites, posttranslational 
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modifications, and variation in p53 family interacting proteins. Thus, we sought to 
identify and characterize p73-interacting proteins as a means to provide 
important insight into the regulatory mechanisms of p73.  Better understanding of 
interacting and regulatory partners of p73 could provide insight into possible 
mechanisms to therapeutically target p73 in cancers in which p53 is mutated.   
Many therapeutic agents are capable of inducing cell death through p73-
mediated apoptosis27.  p73 activity, in cells lacking functional p53, can initiate 
apoptosis in reaction to treatment with captothecin, etoposide, cisplatin, 
doxorubicin, and taxol64.  Thus, if p73 can be successfully activated in tumors 
with mutant p53, it could be considered an attractive target for therapeutic 
development409.   In fact, p73 is often more highly expressed in different tumor 
types relative to normal tissue, and this upregulation correlates with poor patient 
prognosis77.  Current theories suggest that TAp73 is ‘tolerated’ in tumor cells and 
is negatively regulated by the concomitant expression of ∆Np63, ∆Np73, or 
mutant p5391,400,410.  However, we have identified many tumor cell lines and 
tumors that have elevated levels of p73 in the absence of p63 and mutant p53 
expression; thus, other mechanisms of p73 inactivation are in play.  Thus, p73 is 
an attractive therapeutic target that we do not fully understand.  This chapter 
discusses the known interaction of p73 and MDM2 as well as discusses putative 
interacting proteins identified through a yeast two-hybrid screen, with the goal to 
better understand the regulation of p73.    
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 Results 
Known Regulator of p73, MDM2, Inhibition by Nutlin 3 
The levels of p53 are highly dependent upon the rate at which it is 
degraded by the proteosome12.  MDM2 is the E3 ligase that is responsible for 
p53 ubiquitination that leads to its degradation.   Interestingly, p73 is not targeted 
for degradation by MDM2; but the latter has been shown to bind, and reduce the 
function of p73411.  A small molecule inhibitor of the MDM2-p53 interaction, 
Nutlin-3a, has been identified and further shown to induce apoptosis in cell types 
that retain functional p53412; however, Nutlin-3 can also suppress cellular growth 
independent of wild-type p53.  A potential mechanism for the latter is provided by 
the discovery that Nutlin-3a can dissociate p73-MDM2 interactions, resulting in 
elevated levels of p73 activity413 and presumably growth arrest or apoptosis.  It is 
with this knowledge that we sought to understand possible mechanisms for p73 
regulation as well as determine if exploiting the MDM2-p73 interaction could 
provide a method for activating apoptosis in cells lacking functional p53.   
p73 expression is retained within some tumors (typically in those with 
deficient p53 activity), but is not thought to be deregulated in these 
conditions6,414.   A further understanding of how p73 is regulated is important as it 
will lead to a better understanding of p73 function in normal and transformed 
cells, and it may provide therapeutic targets for tumors with mutated p53.  
As proof-of-concept that manipulation of the interaction of p73 and a 
modulatory protein could lead to activation of p73 pro-apoptotic activity, we used 
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Nutlin-3a to disrupt MDM2 and p73 binding.   The Johnston laboratory in the 
Department of Chemistry at Vanderbilt University has developed a novel method 
for synthesis of the Nutlin-3 inhibitors that enables large-scale, relatively 
inexpensive synthesis415.  Thus, through an ongoing collaboration we have been 
able to perform some relatively large-scale experiments in culture with various 
genetically-defined cell lines, to determine if the MDM2-p73 interaction is a 
potential protein-protein interaction to target in tumors with mutated p53.   
Nutlin 3a exists as two enantiomers within the same compound.  One of 
which is significantly more potent than the other, the Johnston group can 
selectively synthesize the two enantiomers of Nutlin that are both present in the 
commercially available Nutlin 3a.  As part of the collaborative studies, we 
determined if the synthesized active enantiomer of the Nutlin inhibitor (henceforth 
defined as (-)- Nutlin 3)415 was comparable to the previously reported Nutlin 
3a412.  We utilized the p53 wild-type HCT116, RKO, and primary human 
mammary epithelial cells (HMEC) cell lines and observed increases in the 
expression of p53 as well as the downstream target of p53, MDM2 (Figure 22A).   
Isogenic lines of HCT116 p53+/+ and HCT116 p53-/- have been used commonly 
as cell line models to characterize p53-dependent activities and biologies416.  We 
utilized these isogenic cell lines to show p53-dependent elevation of known  
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Figure 22. Newly Synthesized (-)- Nutlin 3 Exhibits Comparable Activity to Nutlin 3.  (A) 
HCT116, RKO, and HMEC cells lines were treated with DMSO, (-)- Nutlin 3 and commercially 
available Nutlin 3a.  The levels of p53, Mdm2, and Actin were analyzed by Western blot.  (B) 
The active ((-)- Nutlin 3) and inactive ((+)- Nutlin 3) enantiomer were utilized to treat HCT116 
p53 wild-type and isogenic null cell line. Downstream targets p21 and MDM2 were analyzed 
for p53 activity.  The metabolic activities of cells were measured using Alamar Blue assays 
with treatment of HCT116 cells with either (-)- Nutlin 3 and (+)- Nutlin 3. All data represented 
was collected by Clayton Marshall.   
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targets, p21 and MDM2, after treatment with (-)- Nutlin 3 (Figure 22B).   
  We determined that 1000 nM (-)- Nutlin 3 for eight hours significantly 
activated p53-dependent transcription of downstream targets p21 and MDM2 
(Figure 22B).  The same cell lines required 8000 nM of the inactive enantomer 
(+)- Nutlin 3 for eight hours to give comparable elevations in p53 targets (Figure 
22B).  The viability of these isogenic lines was also measured, and we observed 
that the growth of HCT116 p53+/+ line is most inhibited by the active (-)- Nutlin 3 
and much less so by (+)- Nutlin 3, while the HCT116 p53-/- cell line was not 
growth inhibited either enantiomer of Nutlin 3 (Figure 22B). 
We treated a panel of 28 triple negative breast cancer (TNBC) cell lines as 
well as HMECs with (-)- Nutlin 3 and graphically represented the µM value of 
their IC50 value observed after 72 h of treatment (Figure 23).  Cell lines with 
functional p53, including HMECs, which express all three p53 family members, 
were determined to be most growth inhibited by Nutlin treatment; however, there 
was also a group of p53 mutant/null cell lines that displayed intermediate 
sensitivity, while others were insensitive to (-)- Nutlin 3 (Figure 23).  Western blot 
analysis of 19 of the TNBC cell lines treated with (-)- Nutlin 3 and the p53 
activating chemotherapeutic doxorubicin (Dox)417 indicate that those lines that 
are most sensitive to either drug have retained wild-type p53 that elevates after 
treatment with the genotoxic agent Dox (Figure 24A).  The 15 less sensitive 
TNBC cell lines expressed either mutant p53 or were null for p53 expression 
(Figure 24B).  
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Figure 23: IC50 Values for TNBC Cell Lines Treated with (-)-  Nutlin 3 The IC50` values 
for all TNBC cell lines are graphically represented. Sub-classification of tumor type within 
TNBC of each of the cell lines are annotated by black (basal-like), gray (mesenchymal-
like), white (luminal-like), and orange (immunomodulatory) boxes beneath the respective 
columns.  HMEC primary cells are annotated by a black dot in a white square for 
comparison to the TNBC cells.  In the lowest row of boxes those cells with either mutant or 
p53 loss are noted by purple shaded boxes at the bottom of the graph, and those 
annotated in white have wild-type p53. All data represented was collected by Clayton 
Marshall, Brian Lehmann, and Josh Bauer. 
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Figure 24. Immunoblot Analysis of TNBC Cell Lines after Treatment with 
Doxorubicin and (-)-  Nutlin 3 (A) Cells with at least one wild-type copy of p53 or (B) 
cells with either mutant p53 or which are null for p53 expression were treated for 8 hours 
with 10 µM doxorubicin as well as the IC50 concentration of (-)- Nutlin 3 and  were 
analyzed by Western blot for p53, Mdm2, and Actin.  All data represented was collected 
by Clayton Marshall. 
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The cells expressing wild-type p53 had elevated MDM2 expression, and 
those that did not express functional p53 had variable and low levels of 
expression.  We hypothesize that those TNBC cell lines with functional wild-type 
p53 have the greatest sensitivity to Nutlin.   However, we also wanted to know 
the molecular feature of those lines that had intermediate sensitivity.   Others 
have reported treatment of some TNBC cell lines with Nutlin 3 and their treatment 
regimen  exhibited differential expression of MDM2 within some of the same cell 
lines we tested (e.g. BT549, MDAMB468,MDAMB453 and MDAMB231).  This 
differential expression could be due to treatment with both enantiomers of Nutlin, 
whereas we were utilizing only the active enantiomer (-)- Nutlin 3. 
MDM2 binds p73 but is not capable of ubiquitination or signaling for 
degradation of p73.  The interaction of MDM2 and p73 lead to the sequestration 
of p73 from the nucleus; thus, affecting its transactivation capabilities411.  Thus, 
we hypothesized that cells with intermediate sensitivity may express p73 that is 
functionally reactivated after treatment with (-)- Nutlin.  We focused on lines that 
express some isoform of p73 and retain wild-type p53 (DU4475 and CAL148), 
express mutant p53 (HS578T and BT549) as well as lines that are null for 
expression of p53 (MDAMB436, MDAMB453, and HCC1806) (Figure 23).  We 
observed that CAL148, and MDAMB453 had increased protein levels of the more 
transcriptionally active TAp73β47,418,419 protein after treatment with (-)- Nutlin 3 
(Figure 25A).  p73 has been shown to transcriptionally regulate itself, so it is  
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Figure 25. (-)- Nutlin 3 Activity Affects p73 Protein Levels and p73 
Dependent Activity (A) Representative western blots of TNBC cell lines with WT 
p53 (DU4475 and CAL148), mutant p53 (HS578T), and null for expression of p53 
(MDAMB436, MDAMB453, and HCC1806) treated with either DMSO or (-)- Nutlin 
3.  (B) Proliferation counts of cell lines from above Western blots with either 
control (PSICO shRNA) or p73 shRNA in which the respective IC50 value of (-)- 
Nutlin 3 was added after the cells seated (16h).  Quadruplicate experiments  of 
triplicate counts of cells were averaged and the error bars shown are the standard 
deviation of those 12 cell counts. All data represented was collected by Clayton 
Marshall. 
TAp73α 
Tap73β 	
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likely that Nutlin inhibition of p73-MDM2 binding activates self regulation of p73 
transcription. 
To determine if p73 is responsible for the effect of (-)- Nutlin 3 in the 
somewhat sensitive TNBC cell lines, it was stably knocked down in HS578T, 
BT549, HCC1806, and MDAMB468 by utilizing lentiviral shRNA.  Each of these 
lines were treated with (-)- Nutlin 3 over the period of 96 h.  The cells containing 
non-targeting shRNA (PSICO) exhibited significantly reduced proliferation.  The 
proliferation rate of cells in which p73 was ablated were less sensitive to the 
administration of Nutlin, indicating p73 dependent regulation of proliferation 
(Figure 25B). 
Using RNAi knockdown of p73, our preliminary data suggest that the 
sensitivity to Nutlin in cell lines with mutant and null p53 is p73-dependent. 
Induction of p73-mediated growth arrest or apoptotic function in tumor cells with 
non-functional p53 signaling is an attractive method for treatment of the many 
cancers in which p53 is lost or mutated. 
 Further studies investigating of the shift in expression of isoforms that 
observed in CAL148, HS578T and MDAMB453 (Figure 25) will be of interest.   
Since p73 is not targeted for degradation by MDM2411 it is likely that Nutlin 
induced release of p73 from MDM2 allows for p73 transcriptional activity 
regulating itself75.  It is also possible that the interruption of the p73-MDM2 allows 
for enhanced transcriptional activation and splicing of alternate isoforms of p73 
Understanding the regulatory loop surrounding the p73-MDM2 signaling axis will 
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provide further evidence as to whether the targeting of p73, in p53-deficient 
tumors, by exploiting the MDM2 interaction is a viable therapeutic option.  
Yeast Two-Hybrid Screen to Identify p73 Co-Associated Proteins  
 A yeast two-hybrid screen was performed with ∆Np73β serving as the 
‘bait’ against a library of ‘preys’ generated from a mixture of T47D, MDA-MB-468, 
BT10, and MCF-7 mRNA (Hybridgenics).  The resulting dataset of positive ‘hits’ 
contained 28 possible interactions, from 18 candidate interacting proteins, that 
were above the false discovery threshold (Figure 26).  Evidence that the screen 
was relatively robust came in the form of the following known p73-interacting 
proteins as positive hits: WWOX420,421, WWP1422, WWP2422, YAP423,424, ITCH425, 
and mutant TP53410,426.  Further the cDNAs encoding the known p73-interacting 
proteins contained domains of the interacting proteins previously mapped and 
reported to be required for p73 binding.  Of note, MDM2 is a known binding 
partner of p73 that we did not identify in our two-hybrid given that it interacts with 
the TA domain, which was not present in our bait protein.  
Many of the novel interacting proteins share similar domain structures, 
namely Ubiquitin Interacting Motifs (UIMs) and Coiled Domains (CDs).  Of the 28 
proteins from our two-hybrid screen, 10 contain at least two UIMs, while 11 
contain CDs that reside within the probable binding site, based on overlap of 
multiple positive clones.  Some of the candidate interacting proteins contain both 
CDs and UIMs.  Many known p73-interacting proteins use CDs for protein-protein  
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 Figure 26. Yeast Two-Hybrid Identified Putative Binding Partners of 
∆Np73β . Proteins identified in the yeast two-hybrid using ∆Np73β as bait are 
listed on this table.  The number of fragments bound to the p73 bait are listed in 
the middle column.  The domains within the fragments of interaction are listed in 
the right-most column.  The table is colored depending upon the domains 
observed within the area of bound fragments including Ubiquitin interacting motifs 
(UIM) (blue), Coiled domain (CD) (yellow), both UIM and CD (green) as well as 
unknown domain structures (gray).  Those proteins in red font have previously 
been reported to be found in protein-protein interacting complexes with p73.  
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interactions.  However, UIMs containing proteins have not been published to 
exhibit protein-protein interactions with p73.   
EPN1 
 Both Epsin 1 (EPN1) and Epsin 2 (EPN2) were observed to bind to 
∆Np73B in the yeast two-hybrid screen.  The Epsins are accessory proteins 
involved in Catherin mediated endocytosis.  The Epsins induce bending stress to 
the bilayer of lipids at the membrane creating curvature and directly inducing 
vesicle formation427.  Epsins directly bind to endocytic machinery such as AP2 
adaptors and Catherin itself428,429.  Most cell types express the Epsins with some 
enrichment in the Brain, and keratinocytes430,431.  Subcellular localization studies 
have shown that the Epsin family of proteins have cytoplasmic localization as 
well as punctate staining at the plasma membrane432. EPN1 and 2 localize in the 
nucleus indicating they may play a role in a signaling pathway linking endocytosis 
to regulation of nuclear factors433.  EPN1 binds to the promyelocytic leukemia 
zinc finger protein, a transcription factor, and regulate its function within the 
nucleus429,433.  Transportation into the nucleus has been shown to be increased 
after treatment with the antibiotic leptomycin B indicating nuclear Epsin transport 
is responsive to external signals433,434. Approximately five percent of clathrin 
heavy chain has been shown to be present in the nuclei435 and has been found to 
bind to the p53-responsive promoter and enhances the transactivation of targets 
in a p53-dependent manner436.  EPN1 has been found to directly bind clathrin434.  
We hypothesized that in a similar way Epsin and p73 may be forming a complex 
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that regulates the downstream transactivation of target genes through a common 
binding partner, possibly clathrin.   
 To further investigate the putative interaction of EPN1 with p73, we 
generated a FLAG-tagged EPN1 expression vector and ectopically expressed 
the protein in H1299 cells with TAp73β or ∆Np73β.  The cells were grown for 24 
h, proteins harvested and immunoprecipiations performed p73-specific 
antibodies.  We detected binding of ∆Np73β and FLAG tagged EPN1 (Figure 
27A).  When the cells were immunoprecipitated in the reverse direction, using 
FLAG antibodies, we recapitulated an interaction between ∆Np73 and EPN1 from 
ectopically expressed proteins within H1299s (Figure 27A). 
  The significant increase in p21 reporter activation after ∆Np73β and EPN1 
co-expression is of interest (Figure 27B).  The immunoprecipitated complexes 
observed suggest that EPN1 binding to p73 may be ∆Np73-specific.  These data 
lead to two interesting hypothesis i) EPN1 binds ∆Np73 and acts as an enhancer 
of its activity ii) or EPN1 binds to ∆Np73 and down regulates its binding to the 
canonical p53 binding site allowing for endogenous p53 family members to 
activate the transcription of downstream target genes.  These hypotheses will 
require further experiments to validate and understand the role of the EPN1-p73 
interaction. 
 The TNBC cell line HCC1806 expresses multiple isoforms of p73 at high 
levels and thus is an ideal cell line to initially investigate interactions with 
candidate interacting proteins.  Immunoprecipitation using antibodies directed to  
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Figure 27. p73-EPN1 Interaction and EPN1-Mediated Regulation of p73 
Activity.   (A) H1299 cells were transfected with exogenous expression vectors of 
TAp73β, ∆Np73β, EPN1 (FLAG tagged).  After 48 hours cells were lysed and 
immunoprecipitation (IP) conducted using antibodies for p73 and FLAG as annotated 
at the bottom of the image.  Immunoblot analysis was conducted using antibodies 
generated to recognize FLAG and p73 as annotated on the left.  All data represented 
was collected by Clayton Marshall. 
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Figure 28. Endogenous Validation of p73-EPN1 Interaction (A) Rapidly 
growing HCC1806 were lysed and immunoprecipitated using antibodies directed 
against EPN1 and p73 (Right two lanes).  Immunoblot analysis using antibodies 
generated to recognize p73 and EPN1 as indicated on the left of the image.  
Isoforms (TAp73α, TAp73β, and ∆Np73β) are annotated on the right of the image.  
(B) Three independent siRNA were utilized to ablate the expression of EPN1.  
Immunoblot of lysates generated from MDA-MB-231 and HCC1806 were 
analyzed using antibodies generated to recognize EPN1, p73, and Actin as 
annotated on the left of the images.  All data represented was collected by 
Clayton Marshall. 
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EPN1 as well as p73 indicate that in this cell line EPN1 and p73 can be found in 
complex (Figure 28A).  This cell line provides further evidence that the interaction 
is isoform specific; immunoprecipitation of EPN1 resulted in a band migrating at 
the same weight as ∆Np73β.   
To further characterize the EPN1 and p73 interaction we knocked down 
EPN1 in MDA-MB-231 and HCC1806 with transfection of three EPN1 siRNAs.  In 
MDA-MB-231 cells, reduction of EPN1 also resulted in decreased protein levels 
of all p73 isoforms in similar levels to the knockdown achieved by use of each of 
the independent siRNAs (Figure 28B).  HCC1806 EPN1 knockdown also resulted 
in differential expression levels of p73, but not to the same degree as what was 
observed in the MDA-MB-231s (Figure 28B).  
 Determining the biological significance of the p73 and EPN1 interaction 
will provide insight to a novel p73-interacting protein.   EPN1 has been reported 
to induce bending stress to the bilayer of lipids at the membrane creating 
curvature427.  This function of EPN1 has not been studied in the context of MCCs 
and the curvature of membranes at and around individual cilia. Future 
experiments in MTEC cultures as well as within the context of ciliary biogenesis 
may provide a biological context for the interaction between p73 and EPN1. 
RAP80 
Receptor associated protein 80 (RAP80) is ubiquitously expressed but 
most highly in testis and ovaries437.  RAP80 is associated with the BRCA1-
BARD1 complex and is key to translocation of this complex to sites of DNA 
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damage438.  The translocation of RAP80 to foci of damage is not dependent upon 
BRCA1 but it does require MDC1 and γ-H2AX439,440.  Interestingly, through the 
use of the ∆Np73 knockout mouse, Wilhelm and colleagues observed ∆Np73 to 
co-localize to sites of DNA damage99.  In this study they determined ∆Np73 co-
localized with  γ-H2AX through an interaction with 53BP1. The interaction with 
53BP1 also inhibited the activation of ATM and subsequent phosphorylation of 
p53.  Further study of other co-factors and mechanisms of these interactions 
have not been reported to date. 
Other studies have implicated RAP80 interaction within the p53/MDM2 
complex.  The p53-RAP80 interaction led to an increased level of p53 
ubuqiutination dependent upon MDM2 expression.   This interaction led to the 
degradation of p53441.  Yan and colleagues discovered a noncanonical p53 
response element within the promoter of RAP80 that is responsive to p53 
expression, implicating that the p53-MDM2 autoregulatory feedback loop also 
includes feedback from p53 regulation of RAP80.  This study also showed that 
depletion of RAP80 leads to stabilization of p53 increasing the level of 
transcription of p53 targets as well as downstream apoptosis441.  We hypothesize 
that, RAP80 is a part of a complex that links p73 to the DNA damage response 
pathway providing a link to the earlier work implicating ∆Np73 translocating to 
sites of DNA damage.  Also we hypothesize that, like p53, p73 will be capable of 
transcriptionally activating the expression of RAP80 through a noncanonical 
binding site.         
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Initial experiments investigating the RAP80 and p73 interaction focused on 
exogenous overexpression and immunoprecpitation-based experiments in the 
H1299 cell line.  Cells were transfected with TAp73β, ∆Np73β, and 3xFLAG-
RAP80 alone and in combination.  Protein lysates were immunoprecipitated 
using p73 antibodies, and immunoblot analysis was conducted using antibodies 
that recognize p73 as well as FLAG peptide.  Our data indicate that both isoforms 
of p73 are in complex with RAP80 in the setting of overexpression (Figure 29). 
Furthermore, IF analysis of H1299 cultures showed TAp73β co-localization with 
RAP80 in the nucleus of the cells in which both factors were co-expressed 
(Figure 29).   
To further delineate the role of a p73-Rap80 complex more work needs to 
be completed to verify an interaction of the endogenously expressed protein as 
well as determine the effect of knockdown on the p73 transcriptional activity and 
biological endpoints.  We hypothesize that, like p53, p73 regulates the 
expression of Rap80.  Our data provide rationale to further pursue the interaction 
of p73-Rap80. 
Further investigation of the interaction between TAp73 and RAP80 will 
focus on the DNA damage response pathway as well as the MDM2-p73 
interaction.  We hypothesize that both of these pathways may be connected 
through the regulation of 53BP1 regulation of ATM, which would then regulate the 
interaction of MDM2 and p73.  As stated in the beginning of this Chapter, 
describing our results with the Nutlin-3 inhibitor data, developing a more in depth  
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Figure 29. Exogenous p73-Rap80 Interaction and Co-localization H1299 cells 
were transfected with vectors that overexpress TAp73β, ∆Np73β, as well as 
Rap80 (3xFLAG).  (A) Input, IgG and 1 mg p73 IP were Immunoblotted using 
antibodies directed to recognize FLAG and p73. Representative micrographs of IF 
experiments in which H1299s were co-transfected with TAp73β (green) and 
Rap80 (3xFLAG) (red). DAPI is shown in blue and the overlay of p73 and FLAG 
immunofluorescence channels are shown as the rightmost image.  All data 
represented was collected by Clayton Marshall.   
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understanding of the complex signaling pathway that regulates the MDM2-p73 
provides a window that may be exploited therapeutically in patients with mutated 
p53.   
TAB2 
TAB1 and TAB2 were discovered in 1996 in a yeast two-hybrid system 
using TGF-β activated kinase (TAK1) as bait442.  Upon overexpression of 
TAB1/2/3, the kinase activity of TAK1 increases442,443.   TAB2 has been shown 
not only to mediate activation of TAK1, but also be essential to its deactivation444.  
TAB proteins, through binding with TAK1, are implicated in several distinct 
pathways in response to extracellular signaling, including but not limited to TGF-
β442, NF-κB445,446, and JNK447.  Previous research into the protein-protein 
interactions of TAB proteins has been focused on the binding of 
monoubiquitinated partners through their respective CUE domains448 as well as 
binding to polyubiquitin chains through their respective zinc finger domains449.  
Ectopic expression of TAB2-FLAG and p73 isoforms in H1299 cells 
followed by immunoprecipitation using antibodies for p73 or TAB2, we showed 
that both TAp73β as well as ∆Np73β bind to TAB2 (Figure 30A & B).  As a 
negative control, we overexpressed BAX and did not observe binding of BAX with  
either p73 or TAB2 (Figure 30A and 30B).  We also investigated the localization 
of p73 and TAB2 after ectopic, concurrent overexpression of both proteins in 
H1299s.  We noted nuclear and perinucliar expression of p73 and predominately  
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Figure 30. Exogenous Validation of p73-TAB2 Interaction and Localization 
(A and B).  H1299 cells were transfected with vectors that overexpress TAp73β, 
∆Np73β, BAX, 3xFLAG, as well as TAB2 (3xFLAG).  (A) Input and 1 mg p73 IP 
were Immunoblotted using antibodies directed to recognize FLAG. (B) Input, 1 mg 
IgG IP, and 1 mg FLAG IP were Immunoblotted using antibodies directed to 
recognize p73.  (C) Representative micrographs of IF experiments in which 
H1299s were co-transfected with TAp73β (green) and TAB2 (3xFLAG) (red). 
DAPI is shown in blue and the overlay of p73 and FLAG immunofluorescence 
channels are shown as the rightmost image.  All data represented was collected 
by Clayton Marshall.   
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perinuclear expression of TAB2.  The cells in which we noted perinuclear p73 
were the same cells in which we observed TAB2 overexpression (Figure 30C).   
 We did not observe robust p73-TAB2 complexes in many cell lines initially 
tested.  TAB2 has been shown to be implicated in biological signaling after cells 
have undergone DNA damage450.  Cisplatin  (CDDP) has been shown to activate 
p73 activity in a c-Abl-dependent manner112.   We tested the hypothesis that the 
p73-TAB2 interaction was DNA-damage regulated, and treated cells with CDDP 
and analyzed the proteins.  Initially we noticed a shift in molecular weight of the 
TAB2 protein in some cell lines tested.  Immunoprecipititation of p73 in TNBC 
cells (HCC1806 and MDA-MB231) as well as a rhabdomyosarcoma line (RH30) 
indicated that the interaction of p73 and TAB2 was significantly increased after 
CDDP treatment (Figure 31). As a negative control, stable lines in which p73 has 
been removed using shRNA were also immunoprecipitated for p73 to test 
whether the interaction observed was p73 dependent.  Our data indicate there 
are two TAB2 species on a Western blot in certain cell lines, both of which are 
capable of knockdown with TAB2 specific shRNAs.  ∆Np73 appears to 
preferentially bind to the slower migrating band only (Figure 31).  This expression 
pattern implies that TAB2 may be alternatively spliced and not all variants bind 
p73.  Further experiments are needed to determine the binding domains for the 
interaction ofthese two proteins.    Future experiments to validate the preliminary 
findings and extend them will be necessary to determine the role of the TAB2 and 
p73 interaction under conditions of normal cell growth and DNA damage.   
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Figure 31. Endogenous Validation of p73-TAB2 Interaction.  Isogenic cell 
lines (HCC1806, Rh30, and MDA-MB-231) expressing p73 (control) and those in 
which p73 has been stably removed (shp73), were either untreated or treated with 
cisplatin (CDDP).    IgG IP, 50 µg input, and 2.5 mg p73 IP samples are annotated 
on the bottom of the immunoblot images.  Immunoblot analysis was conducted 
using antibody directed to TAB2.   All data represented was collected by Clayton 
Marshall.   
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Our experiments do not indicate that the levels of TAB2 are altered after 
CDDP treatment, however we do observe a shift in the migration of TAB2 in 
some of the cell lines tested by Western blot.  In previous studies of the signaling 
effect of TAK1, the co-associated TAB proteins have been observed to be 
cytoplasmic as well as nuclear in localization after treatment with TNF-α as well 
as lipopolysaccharide (LPS)451.  Since the levels do not appear to change after 
treatment, but p73-TAB2 complexes are increased.  We hypothesize that the 
localization of TAB2 changes after treatment with CDDP. Exogenously 
overexpressed TAB2 in H1299s did not appear to localize within the nucleus but 
was predominately observed to be present in punctate foci in close proximity to 
the nucleus.  Exogenous overexpression of TAB2 also did not increase p73-
mediated expression of p21, Noxa, or PUMA.  There must be other factors that 
are necessary to induce TAB2 translocation into the nucleus within specific 
biological contexts, so to further determine the functional relevance of TAB2-p73 
interaction we will continue to focus on those treatments that have been shown to 
activate a p73 signaling.  
Conclusions 
Identification of p73-interacting partners provides insight to p73 regulation 
and function and also biological contexts in which p73 may be therapeutically 
targeted.  Also, it will be important to consider the candidate p73-interacting 
proteins in the context of MCC differentiation.  For example, EPN1 has been 
reported to induce bending stress to the bilayer of lipids at the membrane427.  
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This function of EPN1 has not been studied in the context of MCCs and the 
curvature of membranes at and around individual cilia.  RNAseq experiments 
from our investigation of the murine pulmonary epithelium showed that EPN1 
was highly expressed in the tracheal epithelium.  Our data indicate that the 
interaction between EPN1 and p73 may be specific between EPN1 and ∆Np73 
isoforms. However, further experiments in MTEC cultures as well as within the 
context of ciliary biogenesis may also be of great interest to better define the role 
of ∆Np73 within a specific developmental process.  The discovery of p73 
regulation of MCC differentiation has presented a relevant context for future study 
of p73 activity.  We now have model systems of MTEC growth and differentiation 
in culture from p73 wild-type and deficient tracheal cells.  This system will provide 
a much-needed system to the investigation of p73, as we can now directly 
measure the activity of p73 within a developmental process.  The knowledge of 
this role for p73 did not exist at the time of discovery for these candidate 
interacting proteins. Now that we better understand a biological context of p73, it 
will allow for a broadening of the investigation of these interacting proteins into a 
newly discovered biological relevant process dependent upon the transcriptional 
activity of p73.  
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CHAPTER V 
FUTURE DIRECTIONS AND CONCLUSIONS 
Introduction 
Our findings have provided insight to signaling pathways that govern 
epithelial cell differentiation and transformation and offer an exciting starting point 
for subsequent discovery.  MCCs that line the airways provide essential innate 
defense against agents that can drive transformation.  Dysfunction of motile cilia 
has been linked to several human diseases387,402 and, despite its clinical 
significance, little is known about the molecules and signaling pathways that 
govern motile cilogenesis and MCC differentiation.  In the future it will be 
important to determine the cooperative and antagonistic roles of p73 and p63 in 
MCC fate determination.    We further identified multiple putative binding partners 
of p73 that we hypothesize regulate its function in both a tumor setting as well as 
during epithelial cell development.  Placing p73 in a new developmental context 
has provided many new directions to experimentally investigate the complex 
nature of transcription factor regulation; this chapter will outline a few hypotheses 
that should be pursued to better understand the roles and regulation of p73. 
p73 and MCC Differentiation 
Our p73 and Pol II ChIP-seq identified many novel p73 targets linked to 
MCC fate.  We will initially focus on Foxj1, Myb, Mcidas, Traf3ip1 mRNA targets, 
and miR-449, as they have known links to multiciliogenesis programs334,335,346.   
We determined p73 bound to regulatory regions and Pol II to coding regions of 
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these genes in murine tracheal cells.  During the dissertation work, we focused 
specifically on the role of p73 transcriptional regulation of Foxj1.  Future studies 
determining how p73 regulates these mRNA as well as other miRNAs that 
regulate MCC fate will further determine at what stage of MCC differentiation p73 
is critical.  
In the Foxj1 knockout mouse model, basal bodies are amplified but do not 
adequately dock to the cell membrane and cilia are not formed339.  Preliminary IF 
experiments utilizing antibodies directed against the basal body markers 
γ−tubulin as well as Traf3ip1 indicate that our p73-/- mice are deficient of 
amplified basal bodies.  This absence of basal bodies indicates that the role of 
p73 is upstream of that of Foxj1.  It will be of interest to determine the role that 
p73 plays in licensing progenitor cells to become MCCs, both at the level of 
transactivation of FoxJ1 and subsequent basal body amplification as well as the 
necessity for p73 in later steps of MCC differentiation.  Our finding that p73 
directly regulates Foxj1 provides a starting point.  Future experiments with the 
other 105 genes we discovered to be bound by p73 and also observed to be cilia- 
associated genes (Figures 16 and 17) will provide insight into all of the pathways 
in ciliogenesis that are regulated by p73.  In MTEC cultures we can determine the 
effect of the presence or absence (through gene knockdown) of the newly 
identified target genes of p73 (e.g., Myb, Mcidas, Traf3ip1 and mIR-449) on MCC 
differentiation.  These experiments will be necessary to decipher which p73-
dependent gene expression is required for MCC differentiation. 
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Our discovery of p73 expression within a subset of basal cells, as well as 
p73 binding in close proximity to a significant proportion of cilia-associated genes 
within the airway epithelium (Figures 16, 17, and 18), leads us to hypothesize 
that p73 is an apex regulator of ciliogenesis that is regulated through its 
interaction with p63, and without p73, progenitor cells are not licensed to the 
differentiate along MCC lineage.   The predominate isoform of p63 expressed in 
pulmonary epithelium is the suppressive ∆Np63α isoform.  There must be a 
biological switch mechanism by which p73 transcriptional activity is released from 
∆Np63 negative regulation to allow for MCC differentiation. 
Interplay of p73 and p63 Within a Subset of Basal Cells 
Given the known interplay of p73 with p63 and p536, it is important to 
determine the role, if any, of the other two p53 family members in regulating MCC 
differentiation.  Using murine models as well as gene knockout and 
overexpression strategies in well-established cell culture models, we will further 
investigate p53 and p63 roles in MCCs.  Based on our mouse model results, we 
predict that targeting p53 will not have any effect on FoxJ1, Mcidas, miR-449 and 
MYB-mediated MCCs.  To our knowledge, there is not a defect in 
multiciliogenesis in p21 knockout mice nor any observed phenotypes consistent 
with lack of MCCs452,453.  Since we observed a decreased number of basal cells 
and an increased number of ciliated cells in E18.5 mice with p63 knockdown, we 
predict that loss of the predominant isoform of p63 expressed, the repressive ∆N, 
will result in an increase in the activity of TAp73 on target genes and ‘drive’ more 
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stems to early licensing to MCCs.  p63-deficient human bronchial epithelial cells 
are unable to form cultures due to a proliferation defect253.  With this in mind, we 
can attempt to acutely knock out p63 after the cultures are established.  Given 
the results from the p63 knockdown E18.5 mice, we anticipate an increase in 
MCCs and a reduction/loss of secretory, club cells in our cultures.  Since the 
airway epithelium still develops in both p63- and p73-deficient animals, albeit 
skewed in cell type, this suggests: i) a cell that does not depend upon the 
expression of p63 gives rise to the progenitors that get licensed for MCCs 
differentiation in the p63- mice; and/or ii) there is an airway stem cell that does 
not require p63 or p73 activity.  Examination of the airway in p63-/p73- E18.5 
mice would provide insight.  It will be interesting to determine if p73/p63 dual 
knockout mice are even capable of producing an epithelium or if there is a 
projenitor cell that promotes a fully neuroendocrine cell lined epithelium. 
Using the p73-/- mouse model we can begin to separate the independent 
functions of these transcription factors by investigating the profile of p63 binding 
to genomic sites when p73 is absent.  Performing an in situ ChIP-seq of p63 in  
p73-deficient animals and comparing the data to our p63 ChIP from p73+/+ 
animals will begin to indicate the p63 genomic binding that is dependent and 
independent on p73.  Also it will provide insight into the signaling in the basal cell 
population that is retained in the p73-/- animals.  
p63-/- mice are not viable and not suited to in situ tracheal ChIP-seq (due 
to small size of airway in E18.5 mice).  To determine the binding profile of p73 in 
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the absence of p63 from the tracheal epithelium, we could achieve p63 
recombination using inhalable Cre delivery which would targeting directly the 
tracheal epithelium of p63floxE5-7/floxE5-7 mice, and follow with ChIPseq of p73.  
Alternatively, we could also use wild-type MTEC cultures in which we target p63 
using shRNAs to determine the p73 genomic binding sites in the presence and 
absence of p63.  These experiments could be paired with ectopic expression of 
p63 and p73 in MTEC cultures to further determine the regulatory changes in 
mRNA expression under the various experimental conditions. 
During the initial characterization of the p73-/- mice and control wild-type 
animals, we noted that in a majority of the p63-expressing basal epithelial cell 
containing tissues (e.g. mammary and skin), p73 was co-expressed in a 
significant fraction of basal cells.  We hypothesize that the balance of p63 and 
p73 activity is necessary for the proper basal cell homeostatis in the many 
tissues in which they are co-expressed.  
p73 and p63 Regulation of Pulmonary Epithelial Repair After Damage and 
Stress 
Little is known about the interplay of the p53 family members in controlling 
airway epithelium and repair after damage.  We can exploit the tracheobronchial 
epithelium in mouse models and MTEC cultures derived from these mice as 
genetically tractable human airway models.  We can determine if the p53 family  
is expressed and necessary in injury-induced suprabasal expansion in the 
tracheobronchial epithelium.  
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We can use p53 family mouse strains and perform crosses to study MCCs 
in the context of homeostasis and stress-induced repair.  This can allow us to 
answer the following questions:  i) can we gain insight to the signal that dictates 
p73 expression and activity in the basal cells by analyzing p73 before, during, 
and after injury/repair?  Is expression stochastic or due to spatiotemporal growth 
factor gradients that are known upstream activators of p73 (e.g. E2F1)?; ii) how 
do downstream signaling (e.g. Foxj1, Notch, Myb, Mcidas) become attenuated at 
the time of commitment of the undifferentiated basal cells that co-express p73 
and p63?; and iii) what is the signal that attenuates the p63 signaling at the time 
of commitment to MCC differentiation of the basal cells that co-express p73 and 
p63?  Is the loss of the repressive activities of p63 releasing the activity of p73 
licensing MCCs?  Or is it elevation of p73 that outcompetes the antagonistic 
activity of p63? Does TAp73 activity elevate a downstream target gene product 
that in turn downregulates p63?  There are ample data indicating that persistence 
of Notch signaling blocks MCC development, and that loss of Notch results in 
overpopulation of MCCs in the airway (discussed further in following section).  It 
will be important to determine the interplay of p73, p63 and Notch and the 
‘signaling switches’ in the undifferentiated basal cells co-expressing p63 and p73 
that stimulate commitment to MCC cell fate.  
The McKeon group reported the presence of p63-positive cells in the 
bronchiolar epithelium of mice that had been challenged with H1N1 
infection256,454, and demonstrated that these distal stem cells are required for 
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alveolar regeneration within damaged lungs255,257.  Others have shown that 
∆Np63 is necessary for maintenance and regeneration of the airway epithelium 
after damage252,253.   We determined p63-expressing cells in the bronchiolar 
epithelium of our p73-/- with increased concentration in areas of increased 
inflammation and mucus retention observed in adjacent tissue.  These data 
indicate that the lungs of p73-/- mice exist in a state of continual stress or 
damage.   
There are many damaging toxins (e.g. bleomycin, naphtaliene, H1N1, O2, 
and SO2) utilized in murine models to mimic damaging events to pulmonary 
epithelium455.  These damaging events ablate specific cells (naphthalene- Club 
cells; O2-alveolar cells) or all cells (bleomycin, H1N1 and SO2) and require the 
pulmonary progenitor cells to proliferate to re-populate and repair the 
epithelium455.  We can utilize these treatments within the context of p73+/+ and 
p73-/- to determine the ability of the remaining basal cells in the p73-/- mice to 
repopulate the pulmonary epithelium.  Challenging adult mouse airways with 
these damaging agents would give us a timeline to monitor the capacity of cells 
to react in real time.  It will also be of interest to determine the mechanism of 
death that the epithelial cells undergo after treatments with the toxins.  We 
hypothesize that the p53 family will be integral to the process of epithelial 
turnover.  The p73-/- epithelium may exhibit decreased or differential reaction to 
the toxins as compared to p73+/+ animals.  It is also possible that other p53 
family members are responsible for epithelial death or that they are capable of 
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compensating in the p73-deficient animals.  These experiments will further clarify 
the role of the p53 family within the pulmonary epithelial basal cells after a 
damaging event, as well as provide insight to the timeline of p73 activity in MCC 
development. 
The Role of p73 in Inflammatory Response 
p73 knockout mouse models display increased levels of inflammation1,16 
with very little mechanistic follow-up since the original discovery to further 
understand the ramifications of this phenotype.  In one study, Tomasini and 
colleagues used a model of lethal dosage of lipopolysaccharide (LPS) 
intravenously to determine the contribution of p73 to innate immunity.  The 
TAp73-/- mice exhibited higher levels of proinflamatory cytokines in circulation 
and significantly greater mortality as compared to wild-type littermates456.  The 
investigators further determined that the TAp73-/- mice have an impaired 
resolution of inflammatory response due to a role in macrophage polarization456. 
We noted the lungs of our p73-/- mouse are in a constant state of 
inflammation and mucous retention.   At this time we have not determined that 
the inflammatory response is due to the increased level of foreign bodies due to 
the loss of MCCs or if there is a defect in cell lineages that contribute to 
inflammatory responses.  Tracheal administration of LPS is much more mild than 
intravenous administration used in the previous sepsis model work456, tracheal 
administration does not result in a sepsis rather pulmonary-based immune 
activation457,458.  Intratracheal LPS migrates through the epithelial barrier459-463 
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and activates the CD14/TLR-4 complex trigging an inflammatory response464-466.  
This model would be ideal for treatment of the p73-/- mice to determine if there is 
a differential inflammatory response that is p73-dependent.  Comparing the 
inflammatory cells of untreated- and LPS-treated p73+/+ and p73-/- lungs can 
provide a system in which we can start to determine if the inflammation we 
observe is dependent on p73 or if it is secondary to the dysregulation of the cell 
composition of the pulmonary epithelium. 
 Additionally, Foxj1 has been previously reported to regulate T cell 
activation through modulation of the NF-κB pathway, with Foxj1 deficiency 
leading to systemic inflammation and autoimmunity defects401.  Foxj1 
transcriptioanlly regulates IκBβ,  the negative regulator of NF-κB, and in the 
absence of Foxj1 the NF-κB pathway is hyperactive leading to immune 
dysregulation401.   Given our finding that p73 is a direct regulator of Foxj1, future 
studies are needed to evaluate the mechanistic importance of Foxj1 deficiency in 
T cells and the inflammatory defects observed in the p73-/- setting.  
Notch Pathway 
TAp63 and TAp73 can transactivate the Notch ligands Jag1 and Jag2 and 
regulate Notch signaling in neighboring cells52,390.  Another means for interaction 
between the Notch pathway and the p53 family is binding of the Notch 
Intracellular Domain (NICD) by p53 or TAp73 with a resultant inhibition of 
downstream Notch signaling467,468.  A further regulation of Notch and the p53 
family involves activation/repression of the Notch co-activator MAML, which is 
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potentially engaged by p53, p63 and p73469.  A well-studied example of the 
interplay between the p53 family and Notch is the skin, where basal cell self-
renewal and the terminal differentiation gradient are determined in part by 
antagonistic p63/Notch signaling.  Notch is an essential factor in skin 
differentiation, and TAp63 and p53 have been shown to transactivate 
Notch1470,471.  In basal cells of the skin, ∆Np63 can inhibit TAp63 and attenuate 
Notch signaling through binding to Notch target genes472.  We propose that in the 
airway epithelium, ∆Np63 is a major antagonist of differentiation and TAp73 is the 
major driver of MCC differentiation.  An understanding of the interplay of the p53 
family and Notch signaling in lung epithelium will provide molecular insight to 
signaling dysfunction during tumorigenesis and other lung diseases. 
The Notch pathway plays a key role in development and maintenance of 
the lung epithelium238.  There are four Notch receptors (Notch 1-4) and five 
ligands (JAG1, JAG2, DLL1, DLL3, DLL4).  The interaction of ligand and receptor 
causes cleavage of the Notch receptor at the membrane and release of the 
Notch intracellular domain (NICD).  Notch and its ligands are differentially 
expressed in the various cell lineages and tightly regulated through lateral 
crosstalk238,267.  There is evidence for a link between Notch signaling and the 
observed lung phenotype in the p73-/- mice.  When NICD was overexpressed 
within the developing lung, there was a reduction in the numbers of ciliated cells 
with increased club and mucin cells237.  In mice with lung-specific knockout of 
Pofut1 and RBPJK, two activators of Notch, there was an increase in MCCs and 
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neuroendocrine cells and a reduction of club and secretory cells238,473.   
As is the case for all biological systems, the integration of numerous 
signaling networks results in the proper cell function under a given condition.  
The role of p73 in formation and maintenance of airway epithelium was unknown 
prior to our findings and now it is important to determine how p73 is integrated 
with other relevant pathways to control multiciliogenesis in vivo.  Further, it is 
critical to determine the in vivo role of p73 in the injury/repair response in the 
airway epithelium given that disruption of p73-mediated multiciliogensis likely 
contributes to susceptibility conditions (e.g. COPD) that cause predisposition to 
lung cancer.  Combining data from our studies and others171,235,236,251,398, we 
hypothesize that the p63 and p73 signaling axes are critical for differentiated 
airway epithelium; however, they most likely integrate with other signaling 
modules in the lung, with Notch being a primary candidate.  Notch signaling and 
its spatiotemporal regulation have been previously linked to differentiation of the 
adult airway267.  
Our laboratory and others have identified interplay between p63, p73 and 
Notch family signaling.  Notch signaling plays an essential role in cell fate and 
communication.  The p53 family members receive signals from Notch and assist 
in arbitrating stem cell maintenance, differentiation and regulation of tissue 
homeostasis.  The coordinated transactivation of genes by the Notch pathway 
and p53 family is associated with the initiation of cellular programs that lead to 
inhibition of proliferation and/or differentiation in the skin and central nervous 
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system474.  In contrast, Notch-mediated transcription in the absence of p53 family 
signaling is observed in cells in which the proliferative capacity is to be 
maintained and differentiation is biologically unfavorable, as is the case in cancer 
cells.  In the latter scenario, the activity of p53 family members is absent or 
selected against through several mechanisms474. 
The disruption of Notch signaling in airway epithelial progenitor cells 
results in overpopulation with ciliated cells.  We hypothesize that the proper 
coordination of p63, p73 and Notch signaling is required for normal development 
and homeostasis of complex multiciliated epithelium and loss of this coordination 
leads to lack of proper epithelial function.  We can begin to investigate this 
utilizing MTEC culture systems as well as genetic engineered murine models.  
Lung Branching Phenotype 
 Apart from p73 regulation of MCC development, we noted phenotypic 
differences in the branching of the p73-/- adult animals (Figure 32).  Micrographs 
spanning the entire lung of 14 animals were quantified for the number of 
bronchioles observed.  p73+/+ mice averaged 103 bronchiole openings 
throughout the entire section of the lung while p73-/- mice averaged 65 (Figure  
32).  We can generate several hypotheses to explain the differences observed in 
the bronchiole tree.  First, the reduction in branching is due a result of mucus 
retention and inflammation within the lungs of the p73-/- animals, which causes 
inadequate air exchange.  It has been shown that the physical cue of air 
pressure/exchange is a regulator of signaling required for proper pulmonary  
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Figure 32. Quantification of Bronchioles. Images included are representative 
micrographs of whole lungs from p73+/+ and p73-/- animals. Whole lung sections 
including trachea as well as main bronchioles to ensure similar depth of 
sectioning of 14 mice were photographed and the bronchioles were quantified.  
The raw counts are represented in the scatter plot with the lines in black 
demarcating the 25th 50th (median) and 75th percentile values. (•••• p-
value<0.0001).   All data represented was collected by Clayton Marshall.   
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branching475.  Second, p73 signaling is directly involved in the process of 
pulmonary branching.  To begin to determine if there is relevance to testing this 
hypothesis, it will be important to examine embryonic p73-/- and p63-/- animals to  
determine if there are significant changes in utero to the bronchiole branching 
tree.  If defects in branching are present in utero, it will provide insight as to 
whether p73 signaling is regulating more than MCC fate and basal cell regulation 
within the pulmonary epithelium. 
Regulation of p73 Through Protein-Protein Interactions 
Fox proteins act as part of an enhanceosome to drive the transcriptional 
programs of other TFs (e.g. ERα, FOXA1, and GATA3 in breast cancer)476.  Our 
finding that both p63 and p73 directly bind and regulate Myb expression 
prompted us to further explore the potential role of Myb in epithelial cell 
differentiation.  A recent ChIP of Myb and p63 in adenoid cystic carcinomas 
revealed that 81% of p63 binding sites were co-bound by Myb477.  We 
hypothesize that Myb functions within an enhanceosome that contains p63 and 
p73 (and perhaps Mcidas and/or Foxj1) to modulate regions of the chromatin 
surrounding genes required for basal body formation, amplification and core cilia 
gene expression.  Thus, p73 “marks” a transcriptome that includes key regulators 
such as Foxj1 and Myb.  We determined that p73 binds to more than 1700 
promoter sites in basal progenitor cells as well as MCCs1, and that even if Pol II 
is bound at those sites in progenitor cells, it may be ‘paused’ and not elongating 
transcripts until other co-activators are present and/or repressor activity is 
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reduced to activate the transcriptome for MCC differentiation.  We hypothesize 
that co-binding of p63, which is co-expressed with p73 in the basal cells, 
represses transcription of key regulators such as p21 and miR-449 and prevents 
exit from an S-phase state and attenuation of Notch signaling.  Cells must exit 
the cell cycle to allow for basal body amplification and further development of 
individual cilia.  Repression of p73 transcription of cell cycle arrest factors would 
be another mechanism by which downstream factors of ciliogenesis are 
regulated by p73 activity.  For example, Mcidas activity is cell cycle dependent 
and without its activity downstream targets such as FoxJ1 are not 
expressed{Pan, 2014 #1123}.   Of note, ChIP-seq data from whole trachea 
epithelium demonstrate p63 co-binding at 46% of the p73 identified binding 
sites1.  We postulate that there is a signaling event that function as a switch 
(perhaps during injury) to attenuate p63 repressive activity and thus, elevate 
TAp73 activity, driving MCC fate.  This can be formally tested, in part, by 
determining if p73 requires Mcidas as a co-activator to elevate Foxj1 levels and 
Myb levels.  The p73-mediated expression and coordination of Myb and p21 
activity likely enable cell cycle exit and basal body amplification.  Further analysis 
of target genes of Myb and Foxj1 and their proximity of binding to newly 
discovered p73 binding sites will assist in determining if p73 is implicated in a 
complex of protein-protein interactions to act as an enhancesome of 
transcription.   
 The putative binding partners of p73 within our yeast two-hybrid should be 
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further investigated to determine if there are pulmonary-specific roles for their 
biological functions.  For example, Epsins coordinate endocytosis by causing in 
membrane bending to cause invaginations in the cellular membrane431.  They 
mediate signaling from the endocytotic pathway to the nucleus.  MCCs require 
dynamic membrane potential to properly develop membranes that cover the 
chains of actin that make up the individual cilia.  It would be of interest to 
determine if the binding between p73 and Epsin1 and/or Epsin 2 has a further 
role during development of MCC cells and regulation of the membrane of MCCs. 
Results from our tracheal ChIP-seq of p63 and p73 indicated that two of 
the putative binding partners, Cuedc1 and Ubc, of p73 might also be 
transcriptionally regulated by p73.  CUE domain containing 1 (Cuedc1) was first 
described as one of five genes that was differentially expressed in patients with 
metastatic cervical cancer as compared to those without metastatic lesions478. 
Cuedc1 has been observed to be expressed at a significantly lower rate in 
patients with preeclampsia479.  Little else is known about the mechanistic function 
of Cuedc1.  We observed two binding sites for p63 and a single site for p73 
within 25,000 bp or the Cuedc1 TSS (Figure 33).   Polyubiquitin-C (Ubc) is a 
ubiquitin coding gene that is a polyubiquitn precursor.  Ubiquitin is coded by four  
genes.  UBA52 and RPS27A code for single copies of ubiquitin fused to 
ribosomal proteins L40 and S27A respectively480.  UBB and UBC code for 
polyubquitin with head to tail repeats of ubiquitin480.  Polyubquitin is linked 
through different lysine residues within the ubiquitin itself, and the pattern of  
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Figure 33. Tracheal ChIP-seq binding of p73/p63 in Proximity to Cuedc1 and 
Ubc. Integrative Genomics Viewer screenshots for genes identified in the p73 
yeast two-hybrid screen to which p73 and p63 are bound.  The four tracks show 
ChIP-seq data normalized to 1x depth of coverage and presented with identical 
scales. The bottom three tracks represent DNA reads that were obtained after 
ChIP with the antibodies listed to the left, and the top track is the input sample for 
comparison. At the bottom of each panel is an annotated exon/intron gene 
structure displayed on the same scale as the ChIP-seq tracks, and the arrow in 
the bottom left annotates the gene orientation.  Data was generated by Clayton 
Marshall through collaboration with Bryan Venters.  Clayton Marshall was 
assisted in bioinformatic analysis by Scott  Beeler and Timothy Shaver. 
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Lysine linkage regulate the downstream function of the ubiquitination of target 
proteins.  For example, Lys-6 linked polyubuiquitin has been implicated in the 
process of DNA repair439,481, Lys-11 linked ubiquitin is involved in cell cycle 
regulation481, Lys-48 linked ubiquitin leads to proteosomal protein degradation482,  
and Lys-63 linked ubiquitin is involved in endocytosis and DNA damage 
response483. 
These data lead us to hypothesize that p73 may be in an auto-regulatory 
loop with the co-associated proteins Cuedc1 and Ubc by directly regulating their 
transcription.  Function of Cuedc1 is relatively understudied so any insights into 
the function of Cuedc1 would be beneficial for the field.  UBC as a precursor for 
polyubiquitin chains could regulate protein activity both modulation of through 
turn over and activation of function.   Future investigations into these interactions 
and the role in regulating p73 transcriptional activity will be of interest to better 
understand p73 regulation within a defined biological role of MCC differentiation. 
p73 Status in Diseases and Cancer 
To decipher a role of p73 within disease, we must investigate the 
expression of each of the isoforms within diagnosed disease states.  The 
discoveries made as part of this dissertation research led to the conceptually 
innovative hypothesis that p73 functions as a tumor suppressor through 
regulation of novel target gene transcription required for determination of MCC 
fate in complex epithelium.  In this, it is likely that p73 signaling within this cell 
type effects the tissue as a whole, and we must broaden our investigation of p73 
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from cancer-only to include the adjacent “normal” tissue in disease states.   
Numerous motile cilia are located on the apical surface of epithelial cells 
lining select tissues that require fluid movement for proper function.  The 
coordinated beating of multiple motile cilia is essential for mucus/infiltrate 
clearance in the airway, sinus and ears and the prevention of infections and 
inflammation in these tissues373.  In the reproductive tract, dysfunction of motile 
cilia lining the efferent duct and oviduct has been implicated in the sterility of both 
males and females, respectively297,298.  In the brain, lack of ependymal flow due 
to defective motile cilia can cause closure of the cerebral aqueduct and result in 
hydrocephalus and hippocampal dysgenesis220,299,302.  Disruption of ciliated 
epithelium has been linked to several other human diseases, including: primary 
ciliary dyskinesia (PCD)296; Bardet-Biedl syndrome (BBS)484; asthma485-489; 
anosmia402 and chronic obstructive pulmonary disease (COPD)490-492. 
As more and more datasets in which mRNA expression and gene 
mutation have been investigated within diseases and cancer become available, 
we must use our findings implicating p73 in MCCs to focus on tissues and 
diseases of relevance to this biological function of p73.  It is important to  
investigate differential isoform expression within disease and cancer, for 
example, the alternatively spliced N-terminal inactive isoforms ∆ex2p73 and 
∆ex2/3p73.  As a reminder these isoforms are generated when exon 2 or exons 2 
and 3 are alternatively spliced from the full-length p7389,90.  These are of 
particular interest because in NSCLC they are higher expressed while other 
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isoforms are down modulated145.  The study of these isoforms has been 
predominately limited to their role in tumorigenesis, and they have been shown to 
be biologically similar to ∆Np73 and to be preferentially expressed in tumors89-93.  
Studies have indicated that the ∆TAp73 isoforms are upregulated in many cancer 
types and further correlates with poor survival90,97,98.  The focus on these, as well 
as all of the other isoforms must be broadened now that we have discovered 
biological function in MCCs to include tumorigenesis, but not be limited therein.  
Attention must be paid to all diseases in which the functionality of MCCs has 
been compromised to determine if differential p73 expression levels play a 
causative role in disease progression. 
Conclusions 
 The adult lung airway epithelium is composed of a balance of MCCs and 
secretory cells together with undifferentiated basal cells.  The architecture of this 
epithelium is disrupted in many respiratory diseases, several of which predispose 
patients to lung cancer.  The research results presented in this dissertation lay 
the foundation through identification of key signaling pathways that may influence 
individual susceptibility to pulmonary diseases such as COPD and lung cancer. 
Collectively our data provide a unifying mechanism to explain the diverse 
range of phenotypes observed in the p73-deficient mice and place p73 as an 
upstream transcriptional modulator of the many previously identified transcription 
factors required for multiciliogenesis.  Further investigation into the novel p73 
target genes we identified will provide the field mechanistic insights in    to the 
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essential roles of p63 and p73 in the development and maintenance of the airway 
epithelium.  A greater understanding of the protein-protein interactions that 
regulate the function of p73 and p63 will provide clues to control mechanisms or 
biochemical switches that govern the activity of these p53 family members.  The 
most significant contribution of this dissertation to the field is that p73 is required 
for multiciliogenesis.  The collective work provides an appropriate biological 
context in which to further study the biochemical activity and regulation of p73 as 
well as new signaling pathways that may be subverted during tumorigenesis to 
alter basal epithelial cells function and progenitor cell differentiation. 
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